10-K 1 form10-k.htm
false FY 0001509957 Can B Corp 0001509957 2023-01-01 2023-12-31 0001509957 2023-06-30 0001509957 2024-04-12 0001509957 2023-12-31 0001509957 2022-12-31 0001509957 us-gaap:RelatedPartyMember 2023-12-31 0001509957 us-gaap:RelatedPartyMember 2022-12-31 0001509957 us-gaap:SeriesAPreferredStockMember 2023-12-31 0001509957 us-gaap:SeriesAPreferredStockMember 2022-12-31 0001509957 us-gaap:SeriesBPreferredStockMember 2023-12-31 0001509957 us-gaap:SeriesBPreferredStockMember 2022-12-31 0001509957 us-gaap:SeriesCPreferredStockMember 2023-12-31 0001509957 us-gaap:SeriesCPreferredStockMember 2022-12-31 0001509957 us-gaap:SeriesDPreferredStockMember 2023-12-31 0001509957 us-gaap:SeriesDPreferredStockMember 2022-12-31 0001509957 2022-01-01 2022-12-31 0001509957 us-gaap:ProductMember 2023-01-01 2023-12-31 0001509957 us-gaap:ProductMember 2022-01-01 2022-12-31 0001509957 us-gaap:ServiceMember 2023-01-01 2023-12-31 0001509957 us-gaap:ServiceMember 2022-01-01 2022-12-31 0001509957 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2021-12-31 0001509957 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2021-12-31 0001509957 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2021-12-31 0001509957 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2021-12-31 0001509957 us-gaap:CommonStockMember 2021-12-31 0001509957 CANB:CommonStockIssuableMember 2021-12-31 0001509957 us-gaap:TreasuryStockCommonMember 2021-12-31 0001509957 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001509957 us-gaap:RetainedEarningsMember 2021-12-31 0001509957 2021-12-31 0001509957 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2022-12-31 0001509957 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2022-12-31 0001509957 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2022-12-31 0001509957 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2022-12-31 0001509957 us-gaap:CommonStockMember 2022-12-31 0001509957 CANB:CommonStockIssuableMember 2022-12-31 0001509957 us-gaap:TreasuryStockCommonMember 2022-12-31 0001509957 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001509957 us-gaap:RetainedEarningsMember 2022-12-31 0001509957 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2022-01-01 2022-12-31 0001509957 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2022-01-01 2022-12-31 0001509957 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2022-01-01 2022-12-31 0001509957 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2022-01-01 2022-12-31 0001509957 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001509957 CANB:CommonStockIssuableMember 2022-01-01 2022-12-31 0001509957 us-gaap:TreasuryStockCommonMember 2022-01-01 2022-12-31 0001509957 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001509957 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001509957 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2023-01-01 2023-12-31 0001509957 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2023-01-01 2023-12-31 0001509957 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2023-01-01 2023-12-31 0001509957 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2023-01-01 2023-12-31 0001509957 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001509957 CANB:CommonStockIssuableMember 2023-01-01 2023-12-31 0001509957 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-12-31 0001509957 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001509957 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001509957 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2023-12-31 0001509957 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2023-12-31 0001509957 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2023-12-31 0001509957 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2023-12-31 0001509957 us-gaap:CommonStockMember 2023-12-31 0001509957 CANB:CommonStockIssuableMember 2023-12-31 0001509957 us-gaap:TreasuryStockCommonMember 2023-12-31 0001509957 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001509957 us-gaap:RetainedEarningsMember 2023-12-31 0001509957 2023-02-07 2023-02-08 0001509957 CANB:NoCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001509957 CANB:NoCustomerMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001509957 us-gaap:FairValueInputsLevel1Member 2023-12-31 0001509957 us-gaap:FairValueInputsLevel2Member 2023-12-31 0001509957 us-gaap:FairValueInputsLevel3Member 2023-12-31 0001509957 us-gaap:FairValueInputsLevel1Member 2022-12-31 0001509957 us-gaap:FairValueInputsLevel2Member 2022-12-31 0001509957 us-gaap:FairValueInputsLevel3Member 2022-12-31 0001509957 us-gaap:WarrantMember us-gaap:MeasurementInputSharePriceMember 2023-12-31 0001509957 us-gaap:WarrantMember us-gaap:MeasurementInputSharePriceMember 2022-12-31 0001509957 us-gaap:WarrantMember us-gaap:MeasurementInputExercisePriceMember 2023-12-31 0001509957 us-gaap:WarrantMember us-gaap:MeasurementInputExercisePriceMember 2022-12-31 0001509957 us-gaap:MeasurementInputExpectedTermMember 2023-12-31 0001509957 us-gaap:MeasurementInputExpectedTermMember 2022-12-31 0001509957 us-gaap:WarrantMember us-gaap:MeasurementInputPriceVolatilityMember 2023-12-31 0001509957 us-gaap:WarrantMember us-gaap:MeasurementInputPriceVolatilityMember 2022-12-31 0001509957 us-gaap:WarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-12-31 0001509957 us-gaap:WarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-12-31 0001509957 us-gaap:WarrantMember us-gaap:MeasurementInputExpectedDividendRateMember 2023-12-31 0001509957 us-gaap:WarrantMember us-gaap:MeasurementInputExpectedDividendRateMember 2022-12-31 0001509957 us-gaap:WarrantMember 2023-12-31 0001509957 us-gaap:WarrantMember 2022-12-31 0001509957 CANB:ASOPNoteIMember CANB:ArenaSpecialOpportunitiesPartnersOneLPMember 2020-12-31 0001509957 CANB:ASOPNoteIMember CANB:ArenaSpecialOpportunitiesPartnersOneLPMember 2020-12-01 2020-12-31 0001509957 CANB:ASOPNoteIMember CANB:ArenaSpecialOpportunitiesPartnersOneLPMember 2023-01-01 2023-12-31 0001509957 CANB:ASOFNoteIMember CANB:ArenaSpecialOpportunitiesFundLPMember 2020-12-31 0001509957 CANB:ASOFNoteIMember CANB:ArenaSpecialOpportunitiesFundLPMember 2020-12-01 2020-12-31 0001509957 CANB:ASOFNoteIMember CANB:ArenaSpecialOpportunitiesFundLPMember 2023-01-01 2023-12-31 0001509957 CANB:ASOPNoteIIMember CANB:ArenaSpecialOpportunitiesPartnersOneLPMember 2021-05-31 0001509957 CANB:ASOPNoteIIMember CANB:ArenaSpecialOpportunitiesPartnersOneLPMember 2021-05-01 2021-05-31 0001509957 CANB:ASOPNoteIIMember CANB:ArenaSpecialOpportunitiesPartnersOneLPMember 2023-01-01 2023-12-31 0001509957 CANB:ASOFNoteIIMember CANB:ArenaSpecialOpportunitiesFundLPMember 2021-05-31 0001509957 CANB:ASOFNoteIIMember CANB:ArenaSpecialOpportunitiesFundLPMember 2021-05-01 2021-05-31 0001509957 CANB:ASOFNoteIIMember CANB:ArenaSpecialOpportunitiesFundLPMember 2023-01-01 2023-12-31 0001509957 CANB:ASOFNoteIIMember CANB:HoldersMember 2022-04-14 2022-04-14 0001509957 us-gaap:ConvertibleNotesPayableMember CANB:EmpirePropertiesLLCMember 2022-01-01 0001509957 us-gaap:ConvertibleNotesPayableMember CANB:EmpirePropertiesLLCMember 2022-01-01 2022-01-01 0001509957 us-gaap:ConvertibleNotesPayableMember CANB:EmpirePropertiesLLCMember 2023-01-01 2023-12-31 0001509957 CANB:BLNoteMember CANB:BlueLakePartnersLLCMember 2022-03-31 0001509957 CANB:BLNoteMember CANB:BlueLakePartnersLLCMember 2022-03-01 2022-03-31 0001509957 CANB:BLNoteMember CANB:BlueLakePartnersLLCMember 2023-02-27 2023-02-27 0001509957 CANB:BLNoteMember CANB:BlueLakePartnersLLCMember srt:MaximumMember 2023-02-27 2023-02-27 0001509957 CANB:BLNoteMember CANB:BlueLakePartnersLLCMember srt:MinimumMember 2023-02-27 2023-02-27 0001509957 CANB:BLNoteMember CANB:BlueLakePartnersLLCMember 2023-01-01 2023-12-31 0001509957 CANB:MHNoteMember CANB:MastHillFundLPMember 2022-03-31 0001509957 CANB:MHNoteMember CANB:MastHillFundLPMember 2022-03-01 2022-03-31 0001509957 CANB:MHNoteMember CANB:MastHillFundLPMember 2023-02-27 2023-02-27 0001509957 CANB:MHNoteMember CANB:MastHillFundLPMember srt:MaximumMember 2023-02-27 2023-02-27 0001509957 CANB:MHNoteMember CANB:MastHillFundLPMember srt:MinimumMember 2023-02-27 2023-02-27 0001509957 CANB:MHNoteMember CANB:MastHillFundLPMember 2023-01-01 2023-12-31 0001509957 CANB:FMNoteMember CANB:FourthManLLCMember 2022-04-30 0001509957 CANB:FMNoteMember CANB:FourthManLLCMember 2022-04-01 2022-04-30 0001509957 CANB:FMNoteMember CANB:FourthManLLCMember 2023-02-27 2023-02-27 0001509957 CANB:FMNoteMember CANB:FourthManLLCMember srt:MaximumMember 2023-02-27 2023-02-27 0001509957 CANB:FMNoteMember CANB:FourthManLLCMember srt:MinimumMember 2023-02-27 2023-02-27 0001509957 CANB:FMNoteMember CANB:FourthManLLCMember 2023-01-01 2023-12-31 0001509957 CANB:AlumniNoteMember CANB:AlumniCapitalLPMember 2022-06-30 0001509957 CANB:AlumniNoteMember CANB:AlumniCapitalLPMember 2022-06-01 2022-06-30 0001509957 CANB:AlumniNoteMember CANB:AlumniCapitalLPMember 2023-01-01 2023-12-31 0001509957 CANB:WalleyeOpportunitiesMasterFundMember CANB:WalleyeOpportunitiesMasterFundNoteMember 2022-08-31 0001509957 CANB:WalleyeOpportunitiesMasterFundMember CANB:WalleyeOpportunitiesMasterFundNoteMember 2022-08-01 2022-08-31 0001509957 CANB:WalleyeOpportunitiesMasterFundNoteMember CANB:WalleyeOpportunitiesMasterFundMember 2023-01-01 2023-12-31 0001509957 CANB:TysadcoPartnersMember CANB:TysadcoNoteVIMember 2023-01-31 0001509957 CANB:TysadcoNoteVIMember CANB:TysadcoPartnersMember 2023-01-01 2023-01-31 0001509957 CANB:TysadcoNoteVIMember CANB:TysadcoPartnersMember 2023-01-01 2023-12-31 0001509957 CANB:SecuritiesPurchaseAgreementMember CANB:WOMFMember 2023-03-02 0001509957 CANB:SecuritiesPurchaseAgreementMember CANB:WOMFMember 2023-03-02 2023-03-02 0001509957 CANB:SecuritiesPurchaseAgreementMember us-gaap:InvestorMember srt:MaximumMember 2023-03-02 0001509957 CANB:WOMFMember CANB:SecuritiesPurchaseAgreementMember us-gaap:CommonStockMember 2023-03-02 0001509957 CANB:WOMFMember CANB:SecuritiesPurchaseAgreementMember us-gaap:CommonStockMember 2023-09-30 0001509957 CANB:WOMFMember CANB:SecuritiesPurchaseAgreementMember us-gaap:CommonStockMember srt:MinimumMember 2023-03-02 0001509957 CANB:WOMFMember CANB:SecuritiesPurchaseAgreementMember us-gaap:CommonStockMember 2023-03-02 2023-03-02 0001509957 us-gaap:InvestorMember 2023-03-02 0001509957 us-gaap:InvestorMember 2023-03-02 2023-03-02 0001509957 us-gaap:InvestorMember srt:MinimumMember 2023-03-02 0001509957 us-gaap:InvestorMember srt:MaximumMember 2023-03-02 0001509957 CANB:PromissoryNoteMember 2023-05-31 0001509957 CANB:PromissoryNoteMember 2023-05-01 2023-05-31 0001509957 CANB:PromissoryNoteMember 2023-01-01 2023-12-31 0001509957 CANB:ForbearanceAgreementMember 2023-05-31 0001509957 CANB:ForbearanceAgreementMember CANB:DuramedMILLCMember 2023-05-01 2023-05-31 0001509957 CANB:HolderMember CANB:WOMFMember 2023-05-31 0001509957 CANB:HolderMember CANB:WOMFMember 2023-05-01 2023-05-31 0001509957 CANB:PromissoryNoteMember CANB:WOMFMember 2023-05-31 0001509957 CANB:WOMFMember 2023-05-31 0001509957 CANB:HolderMember CANB:WOMFMember CANB:PromissoryNoteMember 2023-05-01 2023-05-31 0001509957 CANB:HolderMember CANB:PromissoryNoteMember CANB:WOMFMember 2023-05-31 0001509957 CANB:EquipmentAcquisitionAgreementMember 2021-08-12 0001509957 CANB:EquipmentAcquisitionAgreementMember 2021-08-11 2021-08-12 0001509957 CANB:EquipmentAcquisitionAgreementMember 2022-12-31 0001509957 CANB:SecuritiesPurchaseAgreementMember us-gaap:InvestorMember 2023-10-27 0001509957 CANB:InitialNoteMember CANB:StockPurchaseAgreementMember srt:MaximumMember 2023-10-27 0001509957 CANB:InitialNoteMember CANB:StockPurchaseAgreementMember us-gaap:CommonStockMember 2023-10-27 2023-10-27 0001509957 CANB:NotesMember us-gaap:InvestorMember 2023-10-27 0001509957 CANB:StockPurchaseAgreementMember 2023-10-27 2023-10-27 0001509957 CANB:StockPurchaseAgreementMember 2023-10-27 0001509957 CANB:InitialNoteMember CANB:StockPurchaseAgreementMember 2023-10-27 0001509957 CANB:InitialNoteMember CANB:StockPurchaseAgreementMember 2023-10-27 2023-10-27 0001509957 2023-10-27 0001509957 CANB:ConsolidatedNoteMember 2023-10-27 2023-10-27 0001509957 CANB:HolderMember CANB:WOMFMember 2023-10-27 0001509957 CANB:PromissoryNoteMember 2023-10-27 2023-10-27 0001509957 CANB:HolderMember CANB:WOMFMember 2023-12-31 0001509957 CANB:PromissoryNoteMember 2023-12-31 0001509957 CANB:UnsecuredPromissoryNoteAgreementMember CANB:LenderMember CANB:DueWithinTwelveMonthsMember 2021-11-18 0001509957 CANB:UnsecuredPromissoryNoteAgreementMember CANB:LenderMember CANB:DueWithinTwelveMonthsMember 2021-11-17 2021-11-18 0001509957 srt:MaximumMember 2022-01-01 2022-12-31 0001509957 srt:MinimumMember 2022-01-01 2022-12-31 0001509957 CANB:LenderMember CANB:UnsecuredPromissoryNoteAgreementMember CANB:DueWithinSixMonthsMember 2022-02-11 0001509957 CANB:LenderMember CANB:UnsecuredPromissoryNoteAgreementMember CANB:DueWithinSixMonthsMember 2022-02-09 2022-02-11 0001509957 CANB:LenderMember CANB:UnsecuredPromissoryNoteAgreementMember CANB:DueWithinSixMonthsMember 2023-12-31 0001509957 CANB:LenderMember CANB:UnsecuredPromissoryNoteAgreementMember CANB:DueWithinThreeMonthsMember 2022-08-18 0001509957 CANB:LenderMember CANB:UnsecuredPromissoryNoteAgreementMember CANB:DueWithinThreeMonthsMember 2022-08-17 2022-08-18 0001509957 CANB:LenderMember CANB:UnsecuredPromissoryNoteAgreementMember CANB:DueOnOctoberThirtyOneTwoThousandTwentyTwoMember 2022-10-14 0001509957 CANB:LenderMember CANB:UnsecuredPromissoryNoteAgreementMember CANB:DueOnOctoberThirtyOneTwoThousandTwentyTwoMember 2023-12-31 0001509957 CANB:LenderMember CANB:UnsecuredPromissoryNoteOneAgreementMember CANB:DueOnOctoberThirtyOneTwoThousandTwentyTwoMember 2022-10-14 0001509957 CANB:LenderMember CANB:UnsecuredPromissoryNoteOneAgreementMember CANB:DueOnOctoberThirtyOneTwoThousandTwentyTwoMember 2023-12-31 0001509957 CANB:LenderMember CANB:UnsecuredPromissoryNoteAgreementMember CANB:DueOnDecemberSeventeenTwoThousandTwentyTwoMember 2022-11-17 0001509957 CANB:LenderMember CANB:UnsecuredPromissoryNoteAgreementMember CANB:DueOnDecemberSeventeenTwoThousandTwentyTwoMember 2023-12-31 0001509957 us-gaap:SeriesAPreferredStockMember 2023-01-01 2023-12-31 0001509957 us-gaap:SeriesAPreferredStockMember 2022-01-01 2022-12-31 0001509957 us-gaap:SeriesBPreferredStockMember 2023-01-01 2023-12-31 0001509957 us-gaap:SeriesDPreferredStockMember 2023-01-01 2023-12-31 0001509957 us-gaap:SeriesDPreferredStockMember 2021-03-27 0001509957 us-gaap:SeriesDPreferredStockMember 2021-02-07 2021-02-08 0001509957 CANB:OfferingMember 2023-01-01 2023-12-31 0001509957 CANB:CommonStockOneMember 2023-01-01 2023-12-31 0001509957 2020-01-01 2020-12-31 0001509957 srt:DirectorMember 2022-01-01 2022-12-31 0001509957 CANB:PasqualeFerroMember CANB:ExecutiveEmploymentAgreementMember 2020-12-26 2020-12-28 0001509957 us-gaap:SeriesCPreferredStockMember CANB:ExecutiveEmploymentAgreementMember 2020-12-28 0001509957 CANB:PhilipScalaMember CANB:ExecutiveEmploymentAgreementMember 2020-12-26 2020-12-28 0001509957 us-gaap:SeriesCPreferredStockMember 2020-12-28 0001509957 CANB:NascentPharmaLLCMember us-gaap:SubsequentEventMember 2024-02-29 0001509957 CANB:NascentMember us-gaap:SubsequentEventMember 2024-02-29 0001509957 CANB:NascentMember us-gaap:SubsequentEventMember 2024-02-01 2024-02-29 0001509957 us-gaap:SubsequentEventMember us-gaap:CommonStockMember 2024-02-01 2024-02-29 0001509957 us-gaap:SubsequentEventMember CANB:ClearThinkMember 2024-02-29 0001509957 us-gaap:SubsequentEventMember 2024-02-29 0001509957 us-gaap:SubsequentEventMember 2024-02-29 2024-02-29 0001509957 us-gaap:SubsequentEventMember 2024-03-14 2024-03-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure CANB:Integer

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K

 

(Mark One)

 

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the Fiscal Year Ended December 31, 2023

 

OR

 

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE

 

For the Transition Period From ____________ to ____________

 

Commission File Number: 000-55753

 

Can B̅ Corp.

(f/k/a Canbiola, Inc.)

(Exact name of registrant as specified in its charter)

 

Florida   20-3624118

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification Number)

 

960 South Broadway, Suite 120, Hicksville NY 11801

(Address of principal executive offices)

 

516-595-9544

Registrant’s telephone number, including area code:

 

None

Securities Registered Pursuant to Section 12(b) of the Act:

 

Tile of each class   Trading Symbol(s)   Name of each exchange on which registered
None   CANB   N/A

 

Securities Registered Pursuant to Section 12(g) of the Act:

Common Stock, Nil par value per share

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company
Emerging Growth Company    

 

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes No

 

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.

 

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

 

The aggregate market value of voting stock held by non-affiliates of the registrant on June 30, 2023, was $1,017,685 based on the last reported sale price of the registrant’s Common Stock on the OTC Markets on that date.

 

As of April 12, 2024, the registrant had outstanding 49,344,230 shares of common stock, $0.00 par value per share.

 

 

 

 
 

 

Can B̅ Corp.

2023 FORM 10-K ANNUAL REPORT

TABLE OF CONTENTS

 

Item No.   Description   Page
         
Cautionary Note Regarding Forward-Looking Statements   3
         
    PART I    
Item 1.   Business.   4
Item 1A.   Risk Factors.   9
Item 1B.   Unresolved Staff Comments.   19
Item 2.   Properties.   19
Item 3.   Legal Proceedings.   20
Item 4.   Mine Safety Disclosures.   20
         
    PART II    
Item 5.   Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.   21
Item 6.   Selected Financial Data.   23
Item 7.   Management’s Discussion and Analysis of Financial Condition and Results of Operations.   23
Item 7A.   Quantitative and Qualitative Disclosures About Market Risk.   24
Item 8.   Financial Statements and Supplementary Data.   24
Item 9.   Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.   24
Item 9A.   Controls and Procedures.   24
Item 9B.   Other Information.   25
         
    PART III    
Item 10.   Directors, Executive Officers and Corporate Governance.   25
Item 11.   Executive Compensation.   28
Item 12.   Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.   29
Item 13.   Certain Relationships and Related Transactions, and Director Independence.   31
Item 14.   Principal Accounting Fees and Services.   31
         
    PART IV    
Item 15.   Exhibits, Financial Statement Schedules.   32
         
Signatures   35

 

2
 

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

Certain statements contained or incorporated by reference in this Annual Report on Form 10-K are considered forward-looking statements (within the meaning of the Private Securities Litigation Reform Act of 1995) concerning our business, results of operations, economic performance and/or financial condition, based on management’s current expectations, plans, estimates, assumptions and projections. Forward-looking statements are included, for example, in the discussions about:

 

  strategy;
  new product discovery and development;
  current or pending clinical trials;
  our products’ ability to demonstrate efficacy or an acceptable safety profile;
  actions by regulatory authorities;
  product manufacturing, including our arrangements with third-party suppliers;
  product introduction and sales;
  royalties and contract revenues;
  expenses and net income;
  credit and foreign exchange risk management;
  liquidity;
  value of assets
  asset and liability risk management;
  the outcome of litigation and other proceedings;
  intellectual property rights and protection;
  economic factors;
  competition; and
  legal risks.

 

Any statements contained in this report that are not statements of historical fact may be deemed forward-looking statements. Forward-looking statements generally are identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “aims,” “plans,” “may,” “could,” “will,” “will continue,” “seeks,” “should,” “predict,” “potential,” “outlook,” “guidance,” “target,” “forecast,” “probable,” “possible” or the negative of such terms and similar expressions. Forward-looking statements are subject to change and may be affected by risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update any forward-looking statement in light of new information or future events, except as required by law, although we intend to continue to meet our ongoing disclosure obligations under the U.S. securities laws and other applicable laws.

 

We caution you that a number of important factors could cause actual results or outcomes to differ materially from those expressed in, or implied by, the forward-looking statements, and therefore you should not place too much reliance on them. These factors include, among others, those described herein, under “Risk Factors” and elsewhere in this Annual Report and in our other public reports filed with the Securities and Exchange Commission. It is not possible to predict or identify all such factors, and therefore the factors that are noted are not intended to be a complete discussion of all potential risks or uncertainties that may affect forward-looking statements. If these or other risks and uncertainties materialize, or if the assumptions underlying any of the forward-looking statements prove incorrect, our actual performance and future actions may be materially different from those expressed in, or implied by, such forward-looking statements. We can offer no assurance that our estimates or expectations will prove accurate or that we will be able to achieve our strategic and operational goals.

 

Forward-looking statements are based on information we have when those statements are made or management’s good faith belief as of that time with respect to future events and are subject to significant risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.

 

Moreover, new risks regularly emerge, and it is not possible for our management to predict or articulate all risks we face, nor can we assess the impact of all risks on our business or the extent to which any risk, or combination of risks, may cause actual results to differ from those contained in any forward-looking statements. All forward-looking statements included in this prospectus are based on information available to us on the date of this Annual Report. Except to the extent required by applicable laws or rules, we undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements contained above and throughout this Annual Report.

 

3
 

 

PART I

 

Item 1. Business

 

Recent Developments

 

In February 2024, our 67% owned subsidiary, Nascent Pharma, LLC (“Nascent”), acquired composition of matter and use patents covering liquid formulations of cannabis, including, among other things, beverages, tinctures, vape pen liquids and liquid filled capsules. Patented uses include using the liquid formulations to alleviate numerous debilitating conditions, including cancer, irritable bowel syndrome, chronic pain, post-traumatic stress disorder, anxiety, sleep disorders and opioid dependencies. Through Nascent, we plan to pursue opportunities to license, protect and develop uses for the patents.

 

An independent valuation firm valued the patents at $122,000,000 in 2020, after taking into account the present value of projected income streams, applying a 90% discount and assuming a revenue stream through August 2034. No assurance can be given that the patents will ultimately provide a revenue stream to the Company or that the value of the patents will equal the value determined by the independent valuation firm.

 

On March 14, 2024, an auction of the assets of our hemp division was conducted under Article 9 of the Uniform Commercial Code following allegations by certain affiliated creditors that we were in breach of our obligations under certain notes and a forbearance agreement. See “Item 3. Legal Proceedings.”

 

Following the auction, we have continued our hemp operations on a reduced scale using equipment provided by third parties and the services of third-party processors. Historically, revenues from our hemp division supported, in part, our durable medical equipment business conducted through Duramed, Inc. Due to reduced support from the hemp division, Duramed, Inc. is operating with reduced staff which has adversely impacted revenues. While we plan to continue our hemp and durable medical equipment operations for the near term, our primary focus will be on protecting and commercializing the cannabis patents recently acquired by Nascent.

 

Organization

 

We were originally incorporated as WrapMail, Inc. (“Wrap”) in Florida on October 11, 2005 in order to tap into a largely un-serviced segment of the web-based advertising industry. Effective January 5, 2015, WRAP acquired 100% ownership of Prosperity Systems, Inc., a New York corporation incorporated on April 2, 2008, in order to acquire Prosperity’s office productivity software suite as a complement to WRAP’s existing intellectual property. After its acquisition, the Company transferred Prosperity’s operations to WRAP; however, the Company does not currently actively operate its WRAP or Prosperity divisions.

 

Around the first quarter of 2017, the Company began to transition into the health and wellness space, including the development, processing and sale of hemp derived products, and now operates three distinct divisions: retail sales, R&D and manufacturing, and durable medical devices. The Company also has a hemp cultivation division which is currently non-operational.

 

On May 15, 2017, WRAP changed its name to Canbiola, Inc. to reflect its transition. On March 6, 2020 CANB changed its name to “Can B̅ Corp.” in order to segregate its corporate identity from its lead products branded under the Canbiola™ brand.

 

Effective December 27, 2010, WRAP effected a 10 for 1 forward stock split of its common stock. Effective June 4, 2013, WRAP effected a 1 for 10 reverse stock split of its common stock. On March 6, 2020, Can B̅ effected a 1 for 300 reverse stock split of its common stock. On March 13, 2022, the Company effectuated a 1 for 15 reverse split of its stock. The accompanying consolidated financial statements retroactively reflect these stock splits.

 

Business Divisions

 

The Company is in the business of promoting health and wellness through its development, manufacture and sale of products containing cannabinoids derived from hemp biomass and the licensing of durable medical devices.

 

Hemp is thought to contain anywhere from 60 to over 100 naturally occurring compounds (cannabinoids) thought to interact with cannabinoid receptors present on the surface of cells in various parts of the central nervous system. The effects of cannabinoids are thought to depend on the area of the brain involved. Cannabidiol (“CBD”) is probably one of the most well-known of these compounds, thought to have many beneficial uses. CBD is incorporated into many of the Company’s products; however, the Company has recently begun extracting and processing cannabinol (“CBN”), cannabigerol (“CBG”), delta-10 and delta-8 for its products and for wholesale to third-parties looking to incorporate such compounds into their products. The Company has all of its hemp based raw materials to incorporate into products tested by a 3rd party independent laboratory. The Company aims to be the premier provider of the highest quality natural hemp cannabinoid products on the market through sourcing the very best raw material and developing a variety of products it believes will improve people’s lives in a variety of areas.

 

  I- Pure Health Products

 

Pure Health Products, LLC, a New York limited liability company (“PHP” or “Pure Health Products”) is the Company’s manufacturing arm. PHP manufactures all of the Company’s CBD products.

 

In December, 2018, the Company acquired 100% of the membership interests in Pure Health Products, with which it then had and currently has an exclusive production agreement, pursuant to an Acquisition Agreement (“PHP Acquisition Agreement”). In January, 2019, PHP acquired certain assets from Seven Chakras, LLC (“Seven Chakras”), a former competitor, which assets included the rights and title to (i) Seven Chakras’ proprietary formulas, methods, trade secrets, and know-how related to the production of Seven Chakras’ CBD products, (ii) Seven Chakras’ tradename, domain name, and social media sites, and (iii) other assets of Seven Chakras including but not limited to raw materials, equipment, packaging and labeling materials, mailing lists, and marketing materials.

 

4
 

 

The Company currently has two in-house branded CBD products that are manufactured by PHP and sold to consumers, Canbiola™ and Pure Leaf Oil™.

 

The Company’s Canbiola™ CBD products are sold via medical professionals under distribution agreements and directly by the Company via its website. The Canbiola™ assets are held directly by the Company and include tinctures, soaps, bath soaks, cryo-gel, salves, massage oils, powders, capsules, and roll-ons.

 

All finished products are stored for time- quality measurement, and each batch of every product is sent to an independent third-party lab for a Certificate of Analysis (“COA”) of the finished products. These COA’s are both listed on our web site and available via the QR code on every retail package.

 

In the 3rd quarter of 2023, the PHP assets were consolidated into the CO Botanicals facility and operations in Fort Morgan, CO and the Lacey, WA facility was closed. Should the Superfood product line acquire new customers, all future production will be from the Fort Morgan Colorado CO Botanicals facilities.

 

  II- Hemp Operating Division

 

The Company’s hemp operating division performs R&D for the Company including for CBN, CBG, delta-8 and delta-10. It also produces industrial hemp and processes hemp biomass, isolate and isomers.

 

Around March 17, 2021, the Company acquired assets through its newly formed, wholly-owned subsidiary, Botanical Biotech, LLC, a Nevada limited liability company (“BB” or “Botanical Biotech”). Such assets include certain materials and manufacturing equipment and marketing or promotional designs, brochures, advertisements, concepts, literature, books, media rights, rights against any other person or entity in respect of any of the foregoing and all other promotional properties, in each case primarily used, developed or acquired by the Sellers for use in connection with the ownership and operation of the BB Assets.

 

Around August 12, 2021, the Company and CO Botanicals LLC, a Nevada limited liability company and wholly owned subsidiary of CANB (“COB”), acquired hemp processing assets from TWS Pharma, LLC, a Wisconsin limited liability company and L7 TWS Pharma, LLC, a Wisconsin limited liability company. COB operates out of Mead, CO.

 

Around August 13, 2021, the Company and TN Botanicals LLC, a Nevada limited liability company and wholly owned subsidiary of CANB (“TNB”), acquired assets from Music City Botanicals, LLC, a Wisconsin limited liability company (“MCB”) including certain equipment, inventory, and intellectual property. In late 2022 the assets from TN Botanicals LLC were moved into consolidated operations under CO Botanicals, LLC in Ft. Morgan, CO.

 

From its Miami lab, the Company processed hemp isolate into isomers such as CBN, CBG, delta-8 and delta-10. At its Tennessee location, the Company produced industrial hemp, processes hemp biomass to isolate, processes isolate to isomers such as CBN, CBG, delta-8 and delta-10, and performed research and development on cannabinoids such as such as CBN, CBG, delta-8, delta-10, CBD and CBDA. At its Colorado facilities, the Company produces industrial hemp and processes hemp biomass to isolate. The biomass and isolate processed by the Company may be produced by the Company or purchased from third parties. All of the Company’s end products contain .3% or less of THC (delta-9). In late 2022 the Company also closed its FL facility and moved the operating assets to Ft. Morgan, CO under the CO Botanicals, LLC operations.

 

  III- Durable Medical Equipment

 

Through its medical device division, Duramed, Inc. (“Duramed”) and Duramed MI LLC, a Nevada limited liability company fka DuramedNJ, LLC (“Duramed MI”), the Company serves the post-surgery medical patient arena aiming to aid in recovery and pain reduction.

 

5
 

 

In November 2018, the Company formed Duramed, Inc. to facilitate the manufacture and sale of durable medical equipment (“DME”) incorporating CBD. On January 14, 2019, Duramed entered into a Memorandum of Understanding (the “Sam MOU”) with Sam International (“Sam”) and ZetrOZ Systems LLC (“ZetrOZ” and, collectively with Sam, the “Manufacturers”). Pursuant to the Sam MOU, the Manufacturers granted Duramed the exclusive right to distribute sam® Pro 2.0 (SA271) and sam® Gel Coupling Patches (UB-14-72) within the United States for the Personal Injury Protection/No Fault Market during the term of the Sam MOU. Duramed has agreed to purchase monthly minimums from the Manufacturers at a price per Unit of $2,447. The exclusivity of the Distribution License granted to Duramed under the Sam MOU was dependent upon meeting the monthly minimum, which did not happen. In addition, Duramed was granted the right to distribute sam® Gel Capture Patches (UB-14-24). Duramed will get rebates of 2%-3% based on the volume of products sold by it. The Company did not meet the monthly minimums as contemplated by the Sam MOU and as such is currently distributing the products on an at-will, non-exclusive basis.

 

On May 29, 2019, the Company created Duramed MI to execute the same business strategy into the no-fault insurance market in New Jersey that it had developed in New York; however, Duramed MI is not currently operating in NJ and fully developed its operations in Michigan. None of Duramed’s products are reimbursable under any federal program. Duramed has also expanded its product offerings to include certain back support braces which are sold to the doctor offices and through no-fault insurance programs.

 

Due to staffing and support funding, the Duramed operations are on a reduced development basis while it continues to service the existing receivables and customer base.

 

  IV- Green Grow Farms

 

Green Grow Farms, Inc., a New York corporation (“GGFI” or “Green Grow”) served as the Company’s hemp cultivation arm. Through GGFI, the Company grew its own hemp in New York and partnered with third party growers in other states whereby GGFI provided the farmers with seed and training and splits profits with the farmers. Currently, it is less expensive to buy crude oil and isolate than to produce such from hemp grown by the Company. Accordingly, the Company has stopped its Green Grow operations in favor of buying raw products from third parties. If and when it makes economic sense to grow its own hemp again, the Company will resume Green Grow operations.

 

  V- Imbibe Wellness Solutions

 

On February 22, 2021, the Company entered into an agreement to purchase additional CBD brand assets from Imbibe Health Solutions, LLC, a Delaware limited liability company. The assets have been placed into the Company’s wholly owned subsidiary, Imbibe Wellness Solutions, LLC, a Nevada limited liability company (fka Radical Tactical LLC) (“Imbibe Wellness”), and include the intellectual property rights, including trademarks, logos, know how, formulations, productions procedures, copyrights, social media accounts, domain names and marketing materials. Previously, Imbibe Wellness had a contract with Forever Brands LLC to produce Longevity Brand Superfood drink mix for Brooke Burke Body, Inc. utilizing sister company Pure Health Products, LLC as the production arm. In late 2023, Forever Brands ceased operations thereby ending the Superfood relationship and product line.

 

  VI. Nascent Pharma, LLC

 

In February 2024, the Company’s 67% owned subsidiary, Nascent Pharma, LLC, acquired patents covering liquid formulations of cannabis. The patents relate to the extraction of pharmaceutically active components from plant materials, and more particularly to the preparation of a botanical drug substance for incorporation into a medicament and for use in pharmaceutical formulations, in particular comprising cannabinoids obtained from cannabis.

 

6
 

 

The patents include both a composition of matter patent and a method of use patent. The composition of matter patent covers liquid formulations of cannabis where the present cannabinoids are more than 95% CBD, THC, CBN, CBDa, THCa, or several combinations thereof. This patent covers beverages, tinctures, vape pen liquids and liquid filled capsules. This constitutes a considerable portion of the hemp and cannabis industry, potentially up to 50%.

 

Patented uses include using the liquid formulations to alleviate numerous debilitating conditions, including cancer, irritable bowel syndrome, chronic pain, post-traumatic stress disorder, anxiety, sleep disorders and opioid dependencies.

 

An independent valuation firm valued the patents at $122,000,000 in 2020, after taking into account the present value of projected income streams, applying a 90% discount and assuming a revenue stream through August 2034. The valuation of the patents included only CBD claims and only in the U.S. No assurance can be given that the patents will ultimately provide a revenue stream to the Company or that the value of the patents will equal the value determined by the independent valuation firm. Since the date of the valuation, the patents have become effective in Canada, Australia, New Zealand, Israel and Brazil and have received additional divisional patents in the U.S. The priority date for the patents stems back to October 2013 and the patents have pending status in the European Union, India, China, Eurasia, South Korea, Mexico, Japan, and Colombia.

 

Of significance, the patents survived an earlier invalidity challenge in Federal Court.

 

Through Nascent, the Company plans to pursue opportunities to license and develop uses for the patents.

 

FDA DISCLAIMER

 

The statements found herein have not been evaluated by the Food and Drug Administration (FDA) and the Company’s products are not intended to diagnose, treat, cure or prevent any disease or medical condition.

 

Competitive Conditions

 

The CBD and cannabis markets are flooded with competition ranging from mom and pop operations to multi-million-dollar conglomerates, many with longer operating histories, more capital and/or more industry knowledge than the Company. The Company hopes to partner with or engage industry specialists to help set it apart from its numerous competitors. The Company believes that one of those points of differentiation will be its 3rd party independent testing “Certificate of Analysis” conducted on all of the CBD isolate products it purchases and posting of those lab results on its website. The three largest CBD companies known to the Company are Elixinol LLC, a UK based company with $37 million revenue, GW Pharmaceuticals also UK based with $19 million revenue, and Aurora Cannabis based in Canada with just over $19 million revenue. The top USA companies include Medical Marijuana, CV Sciences, Gaia Herbs, and Charlotte’s Web with respective revenues of $59, $48, $45, and $17 million. Worthy of note is that Charlotte’s Web is on the shelf right next to us at Northwell Health.

 

Hemp biomass and its derivative products have glutted the US market, benefiting our manufacturing divisions with less expensive product but causing our hemp cultivation and processing division to become financially imprudent until the oversupply issue has resolved. Thus, we have halted operations in such division for the time being but may resume such operations should a sound opportunity present. Although we have contract farm agreements in place to grow and harvest hemp biomass, other raw materials for our finished products have at least three sources of supply in the open market and we have little risk of any ingredient supply at this time.

 

Intellectual Property

 

The Company employs, through its Pure Health Product LLC division product researchers and developers and technology experts who set the quality standards and new product development status and time-line agendas under the direct supervision of the Company’s management team.

 

Other than the patents acquired by Nascent, the Company has not been granted any patents or trademarks by the USPTO or by any patent or trademark office of a foreign nation.

 

7
 

 

Employees

 

The Company, directly or through its subsidiaries, currently has 12 full-time employees.

 

Reports to Security Holders

 

Our common stock is registered under the Exchange Act and we are required to file current, quarterly, and annual reports and other information with the SEC. You may read and copy any document that we file at the SEC’s public reference facilities at 100 F. Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-732-0330 for more information about its public reference facilities. Our SEC filings are available to you free of charge at the SEC’s web site at www.sec.gov. We are an electronic filer with the SEC and, as such, our information is available through the Internet site maintained by the SEC that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC. This information may be found at www.sec.gov and posted on our website at www.canbcorp.com.

 

Government Regulation

 

The cultivation and sale of hemp and hemp products is federally regulated under the United States Farm Bill. The 2018 Farm Bill removed hemp as a Schedule 1 Substance under the Controlled Substances Act; however, rules and regulations relating to manufacture and sale of CBD and other hemp derivative products under the Farm Bill must still be promulgated and are expected to impact the Company’s operations. As the industry and our product lines expand, it is uncertain what other statutory schemes and agencies will start to regulate our products. The FDA currently still considers the addition of CBD to food products, cosmetics, or supplements to be illegal and prohibits the advertisement of CBD products with health claims. The Company must also comply with each state’s laws relating to the sale and manufacture, as applicable, of hemp-based products, with some states allowing the sale of cannabinoid products, some states limiting to medical purposes and some states banning outright. These regulations may affect, among others, the way the Company manufactures and distributes its products, the way the Company is taxed, the way the Company banks, the location of the Company’s facilities, the content and testing of the Company’s products, and the quality of the Company’s services. The Company has not sought or received approval of any of its products from the FDA or any state agency. Should the Company be sanctioned by the FDA or state agencies, it could materially, negatively impact the Company’s operations and revenue sources.

 

We are also subject to general business regulations and laws as well as Federal and state regulations and laws specifically governing the Internet and e-commerce. Existing and future laws and regulations may impede the growth of the Internet, e-commerce or other online services, and increase the cost of providing online services. These regulations and laws may cover sweepstakes, taxation, tariffs, user privacy, data protection, pricing, content, copyrights, distribution, electronic contracts and other communications, consumer protection, broadband residential Internet access and the characteristics and quality of services. It is not clear how existing laws governing issues such as property ownership, sales, use and other taxes, libel and personal privacy apply to the Internet and e-commerce. Unfavorable resolution of these issues may harm our business and results of operations. CBD sales are additionally state regulated for shipping and the Company maintains a current list.

 

Transfer Agent

 

We have engaged Transhare Corporation located at 2849 Executive Drive, Suite 200, Clearwater, FL 33762 as our transfer agent.

 

8
 

 

Item 1A. Risk Factors

 

RISK FACTORS

 

Investing in our securities involves a high degree of risk. Before investing in our securities, you should carefully consider the risks and uncertainties described below, together with all of the other information in this prospectus, including our consolidated financial statements and related notes. If any of the following risks materialize, our business, financial condition, operating results and prospects could be materially and adversely affected. In that event, the price of our common stock could decline, and you could lose part or all of your investment.

 

Risks Related to our Common Stock

 

We are subject to the reporting requirements of federal securities laws, which is expensive.

 

We are a public reporting company in the United States and, accordingly, subject to the information and reporting requirements of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and other federal securities laws, and the compliance obligations of the Sarbanes-Oxley Act. The costs of preparing and filing annual and quarterly reports, proxy statements and other information with the SEC and furnishing audited reports to stockholders causes our expenses to be higher than they would be if we remained a privately-held company.

 

Our stock price may be volatile, which may result in losses to our stockholders.

 

The stock markets have experienced significant price and trading volume fluctuations, and the trading of our common stock has generally been very volatile and experienced sharp share-price and trading-volume changes. The trading price of our securities is likely to remain volatile and could fluctuate widely in response to many factors, including but not limited to the following, some of which are beyond our control:

 

  variations in our operating results;
  changes in expectations of our future financial performance, including financial estimates by securities analysts and investors;
  changes in operating and stock price performance of other companies in our industry;
  additions or departures of key personnel; and
  future sales of our common stock.

 

Domestic and international stock markets often experience significant price and volume fluctuations. These fluctuations, as well as general economic and political conditions unrelated to our performance, may adversely affect the price of our common stock.

 

In the past, plaintiffs have often initiated securities class action litigation against a company following periods of volatility in the market price of its securities. We may, in the future, be the target of similar litigation. Securities litigation could result in substantial costs and liabilities and could divert management’s attention and resources.

 

9
 

 

Our common stock is thinly traded, and in the future, may continue to be thinly-traded, and you may be unable to sell at or near ask prices or at all if you need to sell your shares to raise money or otherwise desire to liquidate such shares.

 

We cannot predict the extent to which an active public market for our common stock will develop or be sustained due to a number of factors, including the fact that we are a small company that is relatively unknown to stock analysts, stock brokers, institutional investors, and others in the investment community that generate or influence sales volume, and that even if we came to the attention of such persons, they tend to be risk-averse and would be reluctant to follow an unproven company such as ours or purchase or recommend the purchase of our shares until such time as we became more seasoned and viable. As a consequence, there may be periods of several days or more when trading activity in our shares is minimal, as compared to a seasoned issuer which has a large and steady volume of trading activity that will generally support continuous sales without an adverse effect on share price. We cannot give you any assurance that a broader or more active public trading market for our common stock will develop or be sustained, or that current trading levels will be sustained.

 

The market price for our common stock may be particularly volatile given that we are a relatively small company and have experienced losses from operations that could lead to wide fluctuations in our share price. You may be unable to sell your common stock at or above your purchase price if at all, which may result in substantial losses to you.

 

We do not anticipate paying any cash dividends.

 

We presently do not anticipate that we will pay any dividends on any of our common stock in the foreseeable future. The payment of dividends, if any, would be contingent upon our revenues and earnings, if any, capital requirements, and general financial condition. The payment of any dividends will be within the discretion of our Board of Directors (the “Board”). We presently intend to retain all earnings to implement our business plan; accordingly, we do not anticipate the declaration of any dividends in the foreseeable future.

 

Our common stock may be subject to penny stock rules, which may make it more difficult for our stockholders to sell their common stock.

 

Broker-dealer practices in connection with transactions in “penny stocks” are regulated by certain penny stock rules adopted by the SEC. Penny stocks generally are equity securities with a price of less than $5.00 per share. The penny stock rules require a broker-dealer, prior to a purchase or sale of a penny stock not otherwise exempt from the rules, to deliver to the customer a standardized risk disclosure document that provides information about penny stocks and the risks in the penny stock market. The broker-dealer also must provide the customer with current bid and offer quotations for the penny stock, the compensation of the broker-dealer and its salesperson in the transaction, and monthly account statements showing the market value of each penny stock held in the customer’s account. In addition, the penny stock rules generally require that prior to a transaction in a penny stock the broker-dealer make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser’s written agreement to the transaction. These disclosure requirements may have the effect of reducing the level of trading activity in the secondary market for a stock that becomes subject to the penny stock rules.

 

We may need additional capital, and the sale of additional shares or other equity securities could result in additional dilution to our stockholders.

 

We may require additional capital for the development and commercialization of our products and may require additional cash resources due to changed business conditions or other future developments, including any investments or acquisitions we may decide to pursue. If our resources are insufficient to satisfy our cash requirements, we may seek to sell additional equity or debt securities or obtain a credit facility. The sale of additional equity securities could result in additional dilution to our stockholders. The incurrence of additional indebtedness would result in increased debt service obligations and could result in operating and financing covenants that would restrict our operations. We cannot assure you that financing will be available in amounts or on terms acceptable to us, if at all.

 

10
 

 

Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.

 

Certain of our executive officers, directors and large stockholders own a significant percentage of our outstanding capital stock. Our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates beneficially own shares representing more than a majority of the eligible votes of the Company. Accordingly, our directors and executive officers have significant influence over our affairs due to their substantial ownership coupled with their positions on our management team and have substantial voting power to approve matters requiring the approval of our stockholders. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This concentration of ownership may prevent or discourage unsolicited acquisition proposals or offers for our common stock that some of our stockholders may believe is in their best interest.

 

If we are unable to implement and maintain effective internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our reported financial information and the market price of our common stock may be negatively affected.

 

As a public company, we are required to maintain internal control over financial reporting and to report any material weaknesses in such internal control. Section 404 of the Sarbanes-Oxley Act requires that we evaluate and determine the effectiveness of our internal control over financial reporting and provide a management report on the internal control over financial reporting. If we have a material weakness in our internal control over financial reporting, we may not detect errors on a timely basis and our consolidated financial statements may be materially misstated. We may not be able to complete our evaluation, testing and any required remediation in a timely fashion. During the evaluation and testing process, if we identify one or more material weaknesses in our internal control over financial reporting, our management will be unable to conclude that our internal control over financial reporting is effective. Moreover, when we are no longer a smaller reporting company, our independent registered public accounting firm will be required to issue an attestation report on the effectiveness of our internal control over financial reporting. Even if our management concludes that our internal control over financial reporting is effective, our independent registered public accounting firm may conclude that there are material weaknesses with respect to our internal controls or the level at which our internal controls are documented, designed, implemented, or reviewed.

 

If we are unable to conclude that our internal control over financial reporting is effective, or when we are no longer a smaller reporting company, if our auditors were to express an adverse opinion on the effectiveness of our internal control over financial reporting because we had one or more material weaknesses, investors could lose confidence in the accuracy and completeness of our financial disclosures, which could cause the price of our common stock to decline. Internal control deficiencies could also result in a restatement of our financial results in the future. We have concluded that are internal controls have not been sufficient; however, we have begun to take steps to remediate such insufficiencies. We have communicated to our accounting review firm and audit that we have accomplished the following: (i) we have transitioned each operating subsidiary to a separate bookkeeping system (QuickBooks) and input data at each operating location on a daily basis vs. previously batching data and inputting at corporate office. Corporate then verifies data prior to accepting, (ii) we have a QuickBooks trained person with who inputs data on a real-time basis but not allowed at subsidiary level to access or make certain changes, (iii) we have installed for the hemp division companies (Botanical Biotech (Miami), TN Botanicals (TN), CO botanicals (CO) daily tracking procedures whereby every ounce and pound of raw materials (biomass or crude) is tracked by lot number from input to processing through to finished product, (iv) our accounts receivable tracking system, which is essentially our Duramed Division receivables, is now tracking by medical device unit number, by doctor, by location, by insurance billing company, and we have a far more refined software track and billing system than we did prior quarters, (v) we have consolidated banking to a master account with our primary bank (M&T Bank) by subsidiary, (vi) we have instituted a new procedure for any payables which requires double confirmation to release any funds for any reason, (vii) and we have changed merchant accounts to a single user to better tie out to bank balances and accounts receivable. ,

 

11
 

 

If securities or industry analysts do not publish research or reports about our business, or if they change their recommendations regarding our stock adversely, our stock price and trading volume could decline.

 

The trading market for our common stock could be influenced by the research and reports that industry or securities analysts publish about us or our business. We do not currently have and may never obtain research coverage by industry or financial analysts. If no or few analysts commence coverage of us, the trading price of our stock would likely decrease. Even if we do obtain analyst coverage, if one or more of the analysts who cover us downgrade our stock, our stock price would likely decline. If one or more of these analysts cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.

 

We may not register or qualify our securities with any state agency pursuant to blue sky regulations.

 

The holders of our shares of common stock and people who desire to purchase them in the future should be aware that there may be significant state law restrictions upon the ability of investors to resell our shares. We currently do not intend to and may not be able to qualify securities for resale in states which require shares to be qualified before they can be resold by our shareholders.

 

We are an “emerging growth company,” and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our common stock less attractive to investors.

 

We are an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act, or the JOBS Act. Section 107 of the JOBS Act provides that we may elect to utilize the extended transition period for complying with new or revised accounting standards and such election is irrevocable if made. As such, we have made the election to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act. Please refer to a discussion under “Risk Factors” of the effect on our financial statements of such election.

 

As an emerging growth company, we are exempt from Section 404(b) of the Sarbanes Oxley Act. Section 404(a) requires Issuers to publish information in their annual reports concerning the scope and adequacy of the internal control structure and procedures for financial reporting. This statement shall also assess the effectiveness of such internal controls and procedures. Section 404(b) requires that the registered accounting firm shall, in the same report, attest to and report on the assessment on the effectiveness of the internal control structure and procedures for financial reporting. As an emerging growth company, we are also exempt from Section 14A (a) and (b) of the Exchange, which require the shareholder approval of executive compensation and golden parachutes.

 

We have elected to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(2) of the JOBS Act, that allows us to delay the adoption of new or revised accounting standards that have different effective dates for public and private companies until those standards apply to private companies. As a result of this election, our financial statements may not be comparable to companies that comply with public company effective dates.

 

We are in default of payment obligations under certain promissory notes.

 

As of December 31, 2023, notes payable with principal amounts totaling $8.9 million were past due. Although only the Arena Entities have elected to pursue remedies against us, no assurance can be given that the other holders will not do so in the future. The institution of collection actions could have a material adverse effect on our business and could force us to seek relief through insolvency or other proceedings.

 

We could face significant penalties for our failure to comply with the terms of our outstanding convertible notes.

 

Our various convertible notes contain positive and negative covenants and customary events of default including requiring us in many cases to timely file SEC reports. In the event we fail to timely file our SEC reports in the future, or any other events of defaults occur under the notes, we could face significant penalties and/or liquidated damages and/or the conversion price of such notes could be adjusted downward significantly, all of which could have a material adverse effect on our results of operations and financial condition, or cause any investment in the Company to decline in value or become worthless.

 

12
 

 

The issuance and sale of common stock upon conversion of our convertible notes may depress the market price of our common stock.

 

If sequential conversions of the convertible notes and sales of such converted shares take place, the price of our common stock may decline, and as a result, the holders of the convertible notes will be entitled to receive an increasing number of shares in connection with conversions, which shares could then be sold in the market, triggering further price declines and conversions for even larger numbers of shares, to the detriment of our investors. The shares of common stock which the convertible notes are convertible into may be sold without restriction pursuant to Rule 144. As a result, the sale of these shares may adversely affect the market price, if any, of our common stock.

 

We have established preferred stock which can be designated by the Company’s Board of Directors without shareholder approval.

 

The Company has 5,000,000 shares of preferred stock authorized. The shares of preferred stock of the Company may be issued from time to time in one or more series, each of which shall have a distinctive designation or title as shall be determined by the board of directors of the Company prior to the issuance of any shares thereof. The preferred stock shall have such voting powers, full or limited, or no voting powers, and such preferences and relative, participating, optional or other special rights and such qualifications, limitations or restrictions thereof as adopted by the board of directors. Because the board of directors is able to designate the powers and preferences of the preferred stock without the vote of a majority of the Company’s shareholders, shareholders of the Company will have no control over what designations and preferences the Company’s preferred stock will have. The issuance of shares of preferred stock or the rights associated therewith, could cause substantial dilution to our existing shareholders. Additionally, the dilutive effect of any preferred stock which we may issue may be exacerbated given the fact that such preferred stock may have voting rights and/or other rights or preferences which could provide the preferred shareholders with substantial voting control over us and/or give those holders the power to prevent or cause a change in control, even if that change in control might benefit our shareholders. As a result, the issuance of shares of preferred stock may cause the value of our securities to decrease.

 

Risks Related to our Business

 

Since we have a limited operating history in our industry, it is difficult for potential investors to evaluate our business.

 

Our short operating history in our industry may hinder our ability to successfully meet our objectives and makes it difficult for potential investors to evaluate our business or prospective operations. As an early-stage company, we are subject to all the risks inherent in the financing, expenditures, operations, complications and delays inherent in a new business. Accordingly, our business and success faces risks from uncertainties faced by developing companies in a competitive environment. There can be no assurance that our efforts will be successful or that we will ultimately be able to attain profitability.

 

We may not be able to raise capital when needed, if at all, which would force us to delay, reduce or eliminate our product development programs or commercialization efforts and could cause our business to fail.

 

We expect to need substantial additional funding to pursue additional product development and launch and commercialize our products. There are no assurances that future funding will be available on favorable terms or at all. If additional funding is not obtained, we may need to reduce, defer or cancel additional product development or overhead expenditures to the extent necessary. The failure to fund our operating and capital requirements could have a material adverse effect on our business, financial condition and results of operations.

 

If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts. Any of these events could significantly harm our business, financial condition and prospects.

 

13
 

 

Our independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern.

 

Our historical financial statements have been prepared under the assumption that we will continue as a going concern. Our independent registered public accounting firm has expressed substantial doubt in our ability to continue as a going concern. Our ability to continue as a going concern is dependent upon our ability to obtain additional equity financing or other capital, attain further operating efficiencies, reduce expenditures, and, ultimately, generate more revenue. The doubt regarding our potential ability to continue as a going concern may adversely affect our ability to obtain new financing on reasonable terms or at all. Additionally, if we are unable to continue as a going concern, our stockholders may lose some or all of their investment in the Company.

 

We depend heavily on key personnel, and turnover of key senior management could harm our business.

 

Our future business and results of operations depend in significant part upon the continued contributions of our senior management personnel. If we lose their services or if they fail to perform in their current positions, or if we are not able to attract and retain skilled personnel as needed, our business could suffer. Significant turnover in our senior management could significantly deplete our institutional knowledge held by our existing senior management team. We depend on the skills and abilities of these key personnel in managing the product acquisition, marketing and sales aspects of our business, any part of which could be harmed by turnover in the future. We do not have any key person insurance.

 

We expect to face intense competition, often from companies with greater resources and experience than we have.

 

The health and wellness and hemp derivative industries are highly competitive and subject to rapid change. The industry continues to expand and evolve as an increasing number of competitors and potential competitors enter the market. Many of these competitors and potential competitors have substantially greater financial, technological, managerial and research and development resources and experience than we have. Some of these competitors and potential competitors have more experience than we have in the development of hemp products, including validation procedures and regulatory matters. Moreover, some of these competitors may have patents or pending patent applications that our products infringe and for which we would need a license to become free to operate. In addition, our products compete with product offerings from large and well-established companies that have greater marketing and sales experience and capabilities than we or our collaboration partners have. If we are unable to compete successfully, we may be unable to grow and sustain our revenue.

 

We have substantial capital requirements that, if not met, may hinder our operations.

 

We anticipate that we will make substantial capital expenditures for research and product development work and acquisitions. If we cannot raise sufficient capital, we may have limited ability to expend the capital necessary to undertake or complete research and product development work and acquisitions. There can be no assurance that debt or equity financing will be available or sufficient to meet these requirements or for other corporate purposes, or if debt or equity financing is available, that it will be on terms acceptable to us. Moreover, future activities may require us to alter our capitalization significantly. Our inability to access sufficient capital for our operations could have a material adverse effect on our financial condition, results of operations or prospects.

 

The Russia-Ukraine and Israel-Hamas wars have disrupted global markets and my adversely impact our ability to obtain financing.

 

On February 24, 2022, Russian military forces invaded Ukraine, and the length, impact, and outcome of the ongoing war in Ukraine is highly unpredictable. On October 7, 2023, Hamas terrorists infiltrated Israel’s border with the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas has also launched extensive rocket attacks on Israeli population and industrial centers located along Israel’s border with the Gaza Strip and in other areas within the State of Israel. These attacks have resulted in extensive deaths, injuries and kidnapping. Following the attack, Israel’s security cabinet declared war against Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks. The intensity and duration of Israel’s current war against Hamas is similarly difficult to predict. As a result of the Russia-Ukraine and Israel-Hamas wars and other geopolitical and macroeconomic events, the global credit and financial markets have experienced volatility and disruptions, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates, and uncertainty about economic stability. If the equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly or more dilutive.

 

Current global financial conditions have been characterized by increased volatility which could negatively impact our business, prospects, liquidity and financial condition.

 

Current global financial conditions and recent market events have been characterized by increased volatility and the resulting tightening of the credit and capital markets has reduced the amount of available liquidity and overall economic activity. We cannot guarantee that debt or equity financing, the ability to borrow funds or cash generated by operations will be available or sufficient to meet or satisfy our initiatives, objectives or requirements. Our inability to access sufficient amounts of capital on terms acceptable to us for our operations will negatively impact our business, prospects, liquidity and financial condition.

 

14
 

 

We will need to increase the size of our organization, and we may experience difficulties in managing any growth we may achieve.

 

As our development and commercialization plans and strategies develop, we expect to need additional research, development, managerial, operational, sales, marketing, financial, accounting, legal, and other resources. Future growth would impose significant added responsibilities on members of management. Our management may not be able to accommodate those added responsibilities, and our failure to do so could prevent us from effectively managing future growth, if any, and successfully growing our company.

 

We may expend our limited resources to pursue a particular product and may fail to capitalize on products that may be more profitable or for which there is a greater likelihood of success.

 

Because we have limited financial and managerial resources, we have focused our efforts on particular products. As a result, we may forego or delay the pursuit of opportunities with other products that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Any failure to improperly assess potential products could result in missed opportunities and/or our focus on products with low market potential, which would harm our business and financial condition.

 

We engage in transactions with related parties and such transactions present possible conflicts of interest that could have an adverse effect on us.

 

We have entered, and may continue to enter, into transactions with related parties for financing, corporate, business development and operational services, as detailed herein. Such transactions may not have been entered into on an arm’s-length basis, and we may have achieved more or less favorable terms because such transactions were entered into with our related parties. We rely, and will continue to rely, on our related parties to maintain these services. If the pricing for these services changes, or if our related parties cease to provide these services, including by terminating agreements with us, we may be unable to obtain replacements for these services on the same terms without disruption to our business. This could have a material effect on our business, results of operations and financial condition.

 

Such conflicts could cause an individual in our management to seek to advance his or her economic interests or the economic interests of certain related parties above ours. Further, the appearance of conflicts of interest created by related party transactions could impair the confidence of our investors, which could have a material adverse effect on our liquidity, results of operations and financial condition.

 

Any inability to protect our intellectual property rights could reduce the value of our technologies and brands, which could adversely affect our financial condition, results of operations and business.

 

Our business is dependent upon our trademarks, trade secrets, the patents recently acquired by Nascent and other intellectual property rights. There is a risk of certain valuable trade secrets being exposed to potential misappropriation. The efforts we have taken to protect our proprietary rights may not be sufficient or effective. Any significant impairment of our intellectual property rights could harm our business or our ability to compete. There is a risk that we may have insufficient resources to counter adequately such misappropriation or infringement through negotiation or the use of legal remedies. It may not be practicable or cost effective for us to fully protect our intellectual property rights in some countries or jurisdictions. If we are unable to successfully identify and stop unauthorized use of our intellectual property, we could lose potential revenue and experience increased operational and enforcement costs, which could adversely affect our financial condition, results of operations and business.

 

Our potential for rapid growth and our entry into new markets make it difficult for us to evaluate our current and future business prospects, and we may be unable to effectively manage any growth associated with these new markets, which may increase the risk of your investment and could harm our business, financial condition, results of operations and cash flow.

 

Our entry into the rapidly growing CBD, CBN, CBG and delta-8 markets may place a significant strain on our resources and increase demands on our executive management, personnel and systems, and our operational, administrative, and financial resources may be inadequate. We may also not be able to effectively manage any expanded operations or achieve planned growth on a timely or profitable basis, particularly if the number of customers using our technology significantly increases or their demands and needs change as our business expands. If we are unable to manage expanded operations effectively, we may experience operating inefficiencies, the quality of our products and services could deteriorate, and our business and results of operations could be materially adversely affected.

 

15
 

 

If we are unable to develop and maintain our brand and reputation for our product offerings, our business and prospects could be materially harmed.

 

Our business and prospects depend, in part, on developing and then maintaining and strengthening our brands and reputation in the markets we serve. If problems with our products or technologies cause customers to experience operational disruption or failure or delays, our brand and reputation could be diminished. If we fail to develop, promote and maintain our brand and reputation successfully, our business and prospects could be materially harmed.

 

If we or any of our suppliers or third parties on which we rely for the development, manufacturing, marketing, or sale of our products fails to comply with regulatory requirements applicable to the development, manufacturing, marketing, and sale of our product candidates, regulatory agencies may take action against us or them, which could significantly harm our business.

 

Our product candidates, along with the development process, the manufacturing processes, labeling, advertising, and promotional activities for these products, are subject to continual requirements and review by the FDA and state and foreign regulatory bodies. Regulatory authorities subject a marketed product, its manufacturer, and the manufacturing facilities to continual review and periodic inspections. We, our suppliers, third-parties on which we rely, and our and their respective contractors, suppliers and vendors, will be subject to ongoing regulatory requirements, including complying with regulations and laws regarding advertising, promotion and sales of products (including applicable anti-kickback, fraud and abuse and other health care laws and regulations), required submissions of safety and other post-market information and reports, registration requirements, Clinical Good Manufacturing Practices (cGMP) regulations (including requirements relating to quality control and quality assurance, as well as the corresponding maintenance of records and documentation), and the requirements regarding the distribution of samples to physicians and recordkeeping requirements. Regulatory agencies may change existing requirements or adopt new requirements or policies. We, our suppliers, third-parties on which we rely, and our and their respective contractors, suppliers, and vendors, may be slow to adapt or may not be able to adapt to these changes or new requirements.

 

Failure to comply with regulatory requirements may result in any of the following:

 

  restrictions on our product candidates or manufacturing processes;
  warning letters;
  withdrawal of the products from the market;
  voluntary or mandatory recall;
  fines;
  suspension or withdrawal of regulatory approvals;
  refusal to approve pending applications or supplements to approved applications that we submit;
  product seizure;
  injunctions; or
  imposition of civil or criminal penalties.

 

We could be subject to costly product liability claims related to our products.

 

Since most of our products are intended for human use, we face the risk that the use of our products may result in adverse side effects to people. We face even greater risks upon further commercialization of our products. An individual may bring a product liability claim against us alleging that one of our products causes, or is claimed to have caused, an injury or is found to be unsuitable for consumer use. Any product liability claim brought against us, with or without merit, could result in:

 

  the inability to commercialize our products;
  decreased demand for our products;
  regulatory investigations that could require costly recalls or product modifications;

 

16
 


 

  loss of revenue;
  substantial costs of litigation;
  liabilities that substantially exceed our product liability insurance, which we would then be required to pay ourselves;
  an increase in our product liability insurance rates or the inability to maintain insurance coverage in the future on acceptable terms, if at all;
  the diversion of management’s attention from our business; and
  damage to our reputation and the reputation of our products.

 

Product liability claims may subject us to the foregoing and other risks, which could have a material adverse effect on our business, results of operations, financial condition, and prospects.

 

The Company could be subject to enforcement action by the FDA and certain state regulatory agencies for its products containing CBD or THC compounds.

 

In 2018, the federal Farm Bill removed hemp as a Schedule I drug under the Controlled Substances Act and hemp may now be grown as a commodity crop, with restrictions; however, the 2018 Farm Bill did not specifically legalize CBD. Until Congress promulgates rules and regulations relating to hemp derived cannabinoids, the “legal” status of such, or the processes the Company may have to implement (and at what expense), are still unknowns. A similar paradigm exists under various state laws with which the Company will have to comply. Further, the FDA currently considers the addition of CBD to food products, cosmetics or supplements to be illegal and also prohibits the advertisement of CBD products with health claims. In addition, the FTC under the Federal Trade Commission Act (“FTC Act”) requires that product advertising is truthful, substantiated and non-misleading. We believe that our advertising meets these guidelines; however, the FTC may bring a challenge at any time to evaluate our compliance with the FTC Act.

 

Further, the FDA has recently increased its review of and enforcement against CBD companies for violations of the Federal Food, Drug, and Cosmetic Act (“FCDA”), particularly with respect to the sale of food products containing CBD, claiming that CBD can treat medical conditions in humans or animals, promoting CBD products as dietary supplements, and adding CBD to human and animal foods. Should the Company become subject to enforcement action by the FDA, it could be forced to spend significant sums defending against such enforcement, pay significant fines and ultimately could be forced to stop offering some or all of its CBD products, which would materially, negatively affect the Company’s business and shareholders’ investments. The FDA can also subject individuals to criminal penalties, including fines and imprisonment, for violating certain provisions of the FDCA related to CBD products. In addition, notwithstanding the intense pressure on FDA to fast-track the CBD approval process, it is likely that the approval process for use of CBD or other cannabinoids in foods, cosmetics or supplements will take years and possible that it could never occur at all.

 

Due to the controversy over the cannabis plant within the United States, we face challenges getting our products into stores and into the hands of the end user.

 

The Company intends to release products that contain CBD derived from hemp that are legal within the U.S. However, it is possible we may face scrutiny and run into issues getting our products into stores due to hesitation by stores to carry any product at all affiliated with the cannabis plant, as well as federal, state and local regulations that may restrict our ability to sell cannabinoid products.

 

The Company’s production of Delta-8 THC and Delta-10 THC could subject it to enforcement action by certain federal and state regulatory agencies.

 

Delta-8 THC and delta-10 THC are cannabis compounds that can cause effects similar to delta-9 THC, the main compound in cannabis that causes psychoactive effects. Delta-8 THC and delta-10 THC can be extracted from either hemp or marijuana, but all of the Company’s delta-8 products are made with hemp containing no more than 0.3% THC. Because of the 2018 Farm Bill, hemp can be legally grown and used for extractions all over the United States. Notwithstanding the foregoing, the legality of hemp-derived delta-8 THC and delta-10 THC is in a gray area and varies from state-to-state, with some states allowing, some not addressing specifically, and others banning due to similarity to delta-9 THC. Although the federal legality of delta-8 THC and delta-10 THC is still unclear, the FDA has recently issued Warning Letters to five companies for selling products labeled as containing delta-8 tetrahydrocannabinol, noting that delta-8 THC has psychoactive and intoxicating effects and may be dangerous to consumers. The Warning Letters were primarily targeted at companies marketing the compound as unapproved treatments for various medical conditions or for other therapeutic uses, without adequate directions for use, or the addition of delta-8 THC in foods. Should the Company become subject to enforcement action by federal or state agencies, it could be forced to spend significant sums defending against such enforcement and ultimately could be forced to stop offering some or all of its delta-8 THC and/or delta-10 THC products and/or be subject to other civil or criminal sanctions, which would materially, negatively affect the Company’s business and shareholders’ investments.

 

17
 

 

The novel coronavirus disease of 2019 (“COVID-19”) has had, and continues to have, broad impacts on multiple sectors of the global economy, making it difficult to predict the extent of its impact on our business.

 

On January 30, 2020, the World Health Organization (“WHO”) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the “COVID-19 outbreak”) and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally.

 

The full impact of the COVID-19 outbreak continues to evolve as of the date of this Report. As such, it is uncertain as to the full magnitude that the pandemic will have on our financial condition, liquidity, and future results of operations. Management is actively monitoring the impact of the global situation on our financial condition, liquidity, operations, suppliers, industry, and workforce. Given the daily evolution of the COVID-19 outbreak and the global responses to curb its spread, we are not able to estimate the effects of the COVID-19 outbreak on our results of operations, financial condition, or liquidity for the foreseeable future. We have experienced negative impacts from COVID in the form of reduced sales, delayed operations, inability to effectuate certain business plans, supply chain issues and the like.

 

Our acquisitions may expose us to unknown liabilities.

 

Because we have acquired, and expect generally to acquire, all (or a majority of) the outstanding securities of certain of our acquisition targets, our investment in those companies are or will be subject to all of their liabilities other than their respective debts which we paid or will pay at the time of the acquisitions. If there are unknown liabilities or other obligations, our business could be materially affected. We may also experience issues relating to internal controls over financial reporting that could affect our ability to comply with the Sarbanes-Oxley Act, or that could affect our ability to comply with other applicable laws.

 

If we fail to comply with government laws and regulations it could have a materially adverse effect on our business.

 

Our industry is subject to extensive federal, state and local laws and regulations that are extremely complex and for which, in many instances, the industry does not have the benefit of significant regulatory or judicial interpretation. We exercise care in structuring our operations to comply in all material respects with applicable laws to the extent possible. We will also take such laws into account when planning future operations and acquisitions. The laws, rules and regulations described above are complex and subject to interpretation. In the event of a determination that we are in violation of such laws, rules or regulations, or if further changes in the regulatory framework occur, any such determination or changes could have a material adverse effect on our business. There can be no assurance however that we will not be found in noncompliance in any particular situation.

 

Any failure to comply with all applicable federal and state anti-kickback laws may result in fines and other liabilities, which may adversely affect the Company’s results of operations and reputation.

 

The federal anti-kickback statute (the “AKS”) applies to Medicare, Medicaid and other state and federal programs. AKS prohibits the solicitation, offer, payment or receipt of remuneration in return for referrals or the purchase, or in return for recommending or arranging for the referral or purchase, of goods, including drugs, covered by the federal health care programs. At present, the Company does not participate in any federal programs and its products are not reimbursed by Medicare, Medicaid or any other state or federal program. The AKS is a criminal statute with criminal penalties, as well as potential civil and administrative penalties. The AKS, however, provides several statutory exceptions and regulatory “safe harbors” for particular types of transactions. Many states have similar fraud and abuse laws and their own anti-kickback laws, some of which can apply to all payors, and not just governmental payors. While the Company believes that it is in material compliance with both federal and state AKS laws, the AKS laws present different levels of risks as to two of the Company’s lines of business: (1) sale of the Company’s medical foods, and (2) sale of the Company’s medical devices.

 

18
 

 

 

At present, the Company’s products are not reimbursable under any federal program. If, however, that changes in the future and it were determined that the Company was not in compliance with the AKS, the Company could be subject to liability, and its operations could be curtailed, which could have a material adverse effect on the Company’s business, financial condition and results of operations. Moreover, if the activities of its customers or other entity with which the Company has a business relationship were found to constitute a violation of the AKS and the Company, as a result of the provision of products or services to such customer or entity, were found to have knowingly participated in such activities, the Company could be subject to sanctions or liability under such laws, including civil and/or criminal penalties, as well as exclusion from government health programs. As a result of exclusion from government health programs, neither products nor services could be provided to any beneficiaries of any federal healthcare program.

 

We may not maintain sufficient insurance coverage for the risks associated with our business operations.

 

Risks associated with our business and operations include, but are not limited to, claims for wrongful acts committed by our officers, directors, and other representatives, the loss of intellectual property rights, the loss of key personnel, risks posed by natural disasters and risks of lawsuits from customers who are injured from or dissatisfied with our products. Any of these risks may result in significant losses. We cannot provide any assurance that our insurance coverage is sufficient to cover any losses that we may sustain, or that we will be able to successfully claim our losses under our insurance policies on a timely basis or at all. If we incur any loss not covered by our insurance policies, or the compensated amount is significantly less than our actual loss or is not timely paid, our business, financial condition and results of operations could be materially and adversely affected.

 

Our ability to service our indebtedness will depend on our ability to generate cash in the future.

 

Our ability to make payments on our indebtedness will depend on our ability to generate cash in the future. Our ability to generate cash is subject to general economic and market conditions and financial, competitive, legislative, regulatory and other factors that are beyond our control. Our business may not generate sufficient cash to fund our working capital requirements, capital expenditure, debt service and other liquidity needs, which could result in our inability to comply with financial and other covenants contained in our debt agreements, our being unable to repay or pay interest on our indebtedness, and our inability to fund our other liquidity needs. If we are unable to service our debt obligations, fund our other liquidity needs and maintain compliance with our financial and other covenants, we could be forced to curtail our operations, our creditors could accelerate our indebtedness and exercise other remedies and we could be required to pursue one or more alternative strategies, such as selling assets or refinancing or restructuring our indebtedness. However, such alternatives may not be feasible or adequate.

 

Item 1B. Unresolved Staff Comments

 

Not applicable.

 

Item 2. Properties

 

The Company does not currently own any real property. We do, however, lease office space in Hicksville, New York on a month to month basis following the termination of our lese in December 2023. We have reached an agreement in principle with the landlord pursuant to which we would move into smaller space in the same facility and our rent would be reduced from $3,917 to $1,562 per month. The Company has leases for two additional properties, as described below.

 

CO Botanicals, LLC (“COB”), a wholly owned subsidiary of Can B̅ Corp. leases the real properties located at 17171 County Road 21, Fort Morgan, CO 80701 (out of which PHP operates) and 12555 Energy Road, Fort Morgan, CO 80701 (collectively, the “Fort Morgan Properties”) on a month-to-month basis. Base rent for the Fort Morgan Properties is $14,500 per month.

 

19
 

 

Item 3. Legal Proceedings

 

On April 28, 2021, the Company was served with a commercial legal action against the Company and certain officers by David Weissberg and Donna Marino, who are investors in the Company (collectively, the “Investors”). The complaint was filed in the Supreme Court of the State of New York, County of Nassau, Index No. 605191/2021. The complaint alleges four causes of action.

 

The first cause of action alleges that the Company breached Securities Purchase Agreements with the Investors by failing to assist the Investors in getting opinion letters to remove the restrictive legends from their shares, even though the Company made introductions and requests to the Company’s counsel, provided supporting documents for the Investor’s shares, and ultimately the opinion letters could not be rendered because the Investors failed to submit required documentation to counsel.

 

The second cause of action is similar to the first but related to alleged misrepresentations regarding removing the restrictive legends from shares that were issued for services rather than purchased.

 

The third cause of action alleges that the Company mislead the Investors to invest $500,000. The final cause of action alleges that officers of the Company made misrepresentations regarding the value of the Company’s stock, which caused David Weissberg to owe more in taxes than he was expecting.

 

We have consulted with attorneys and believe the Investors’ claims are meritless, factually inaccurate, and frivolous. We intend to vigorously defend ourselves against the aforementioned legal action and will likely bring counterclaims against the Investors.

 

Approximately November 24, 2021, a vendor of the Company filed amended suit against the Company in Florida, Case No. 2021 CA 001797, for monies allegedly owed and civil theft relating to such monies and related products and fraud in the inducement. We do not believe we owe such vendor any amount. The court has entered a default judgement against the Company for our failure to timely answer the complaint, which default has since been overturned. Subsequently the case has been set for interrogatories and document production which activities are being fulfilled.

 

On or about August 11, 2022, a Complaint was filed by Evexia Plus, LLC against Can B Corp. in a product payment trade dispute. Case Number 63-CV-2022-900692.00 in the Circuit Court of Tuscaloosa County, AL. On 1-26-2023 the court ordered a Summary Judgement in the amount of $336,924. The parties are trying to work out a payment schedule tied to production to satisfy the judgement.

 

On December 1, 2023,the Company, received a notice from Arena Special Opportunities Partners I, LP, Arena Special Opportunities Fund, LP and Arena Investors, LP (collectively, the “Arena Entities” or “Arena”) advising that by virtue of defaults in the performance of the obligations of the Company and its subsidiaries to the Arena Entities, the Arena Entities intended to conduct a public auction of certain assets of the Company and its subsidiaries under Article 9 of the Uniform Commercial Code.

 

The Arena Entities collectively hold approximately $3,838,770 aggregate principal amount of Convertible Notes (the “Arena Notes”) issued by the Company. The Arena Entities previously notified the Company and its subsidiaries that they were in default of certain obligations under the Forbearance Agreement dated February 27, 2023 among the Company, its subsidiaries and the Arena Entities pursuant to which the Arena Entities agreed to forbear from exercising remedies under the Arena Notes until December 31, 2024 provided that no defaults occurred under the Arena Notes or the Forbearance Agreement. The alleged defaults include a failure to deliver account control agreements, failure to enter into a servicing agreement, failure to timely make certain payments and the unauthorized use and misuse of receivable assigned to the Arena Entities.

 

On February 27, 2024, the Supreme Court, County of New York (the “Court”), denied a motion made by the Company seeking a temporary restraining order and preliminary injunction to halt the proposed sale. As a result of the decision, the Arena Entities proceeded with its proposed auction of the Company’s hemp division assets and the auction took place on March 14, 2024. Approximately $300,000 of proceeds were generated by the sale.

 

On April 7, 2024, Arena filed a complaint in the Court against the Company, it subsidiaries and certain officers of the Company and its subsidiaries alleging tortious interference with the auction and seeking a declaratory judgment that the Company is in breach of the Arena Notes and the Forbearance Agreement and that Arena has the right to auction certain equipment held at a Company facility that is not owned by the Company or any of its subsidiaries. The Company believes that Arena’s claims are without merit and intends to vigorously defend Arena’s claims.

 

Other than above, we are not aware of any pending or threatened legal proceedings in which we are involved.

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

20
 

 

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

 

Market Information

 

Our common stock is listed for quotation on OTC Market’s OTCQB® Venture Market under the symbol “CANB.” Our common stock began trading in April 2011. Trading in our common stock has historically lacked consistent volume, and the market price has been volatile.

 

Record Holders

 

As of April 12, 2024, there were 49,344,230 shares of common stock issued and outstanding and held by approximately 250 shareholders of record.

 

Dividends

 

The Company paid $0 in in-kind dividends on its Series B Preferred Stock by the issuance of common stock to the Series B holders in 2020 and 2019. Each share of Series B Preferred Stock has the first preference to dividends, distributions and payments upon liquidation, dissolution and winding-up of the Company, and is entitled to an accrued cumulative but not compounding dividend at the rate of 5% per annum whether or not declared. After six months of the issuance date, such share and any accrued but unpaid dividends can be converted into common stock at the conversion price which is the lower of (i) $0.0101; or (ii) the lower of the dollar volume weighted average price of CANB common stock on the trading day prior to the conversion day or the dollar volume weighted average price of CANB common stock on the conversion day. The Series B Preferred Stock have no voting rights. There are no currently outstanding shares of Series B Preferred Stock*.

 

We do not anticipate paying any cash dividends in the foreseeable future. Except for its Series B Preferred Stock, of which there are none issued and outstanding*, the payment of dividends is within the discretion of our Board of Directors and will depend on our earnings, capital requirements, financial condition, and other relevant factors. There are no restrictions that currently limit our ability to pay dividends on our common stock other than those generally imposed by applicable state law.

 

* It has come to our attention that the Company’s transfer agent still shows 227,590 Series B Preferred shares as being held by RedDiamond Partners LLC (“RedDiamond”) due to an administrative oversight. Nonetheless, such shares were retired in exchange for 97,608 shares of common stock and rights to acquire an additional 35,667 shares of common stock issued to RedDiamond pursuant to an Exchange Agreement dated August 13, 2019.

 

Securities Authorized for Issuance under Equity Compensation Plans

 

On July 28, 2020, the Company adopted an Incentive Stock Option Plan (“ISO”). The purpose of this Can B Corp. 2020 ISO (the “Plan”) is to attract, retain, and motivate employees, officers, directors, consultants, agents, advisors and independent contractors of the Company and its Related Companies by providing them the opportunity to acquire a proprietary interest in the Company and to align their interests and efforts to the long-term interests of the Company’s stockholders. The Plan is administered by the Compensation Committee or, in the Board’s sole discretion, the Board. The Compensation Committee shall be composed of two or more directors, each of whom is a “non-employee director” within the meaning of Rule 16b-3(b)(3) promulgated under the Exchange Act, or any successor definition adopted by the Securities and Exchange Commission. As used in this Plan, the term “Compensation Committee” shall be construed as if followed by the words “(if any);” and nothing in this Plan requires the Board to have a Compensation Committee. Except for the terms and conditions explicitly set forth in the Plan and to the extent permitted by applicable law, the Committee shall have full power and exclusive authority, subject to such orders or resolutions not inconsistent with the provisions of the Plan as may from time to time be adopted by the Board or a Committee composed of members of the Board, to (i) select the Eligible Persons to whom Awards may from time to time be granted under the Plan; (ii) determine the type or types of Award to be granted to each Participant under the Plan; (iii) determine the number of shares of Preferred Stock and/or Common Stock (collectively, “Stock”) to be covered by each Award granted under the Plan; (iv) determine the terms and conditions of any Award granted under the Plan; (v) approve the forms of notice or agreement for use under the Plan; (vi) determine whether, to what extent and under what circumstances Awards may be settled in cash, shares of Preferred Stock and/or Common Stock or other property or canceled or suspended; (vii) determine whether, to what extent and under what circumstances cash, shares of Stock, other property and other amounts payable with respect to an Award shall be deferred either automatically or at the election of the Participant; (viii) interpret and administer the Plan and any instrument evidencing an Award, notice or agreement executed or entered into under the Plan; (ix) establish such rules and regulations as it shall deem appropriate for the proper administration of the Plan; (x) delegate ministerial duties to such of the Company’s employees as it so determines; and (xi) make any other determination and take any other action that the Committee deems necessary or desirable for administration of the Plan. Subject to adjustment from time to time, a maximum of two thousand (2,000) shares of Class C Preferred Stock and, effective as of February 8, 2024, one hundred ten million (110,000,000) shares of Common Stock are available for issuance under the Plan. Shares issued under the Plan shall be drawn from authorized and unissued shares or shares now held or subsequently acquired by the Company as treasury shares. The Committee shall also, without limitation, have the authority to grant Awards as an alternative to or as the form of payment for grants or rights earned or due under other compensation plans or arrangements of the Company. Subject to earlier termination in accordance with the terms of the Plan and the instrument evidencing the Option, the maximum term of an Option shall be ten years from the Grant Date. An Award may be granted to any employee, officer or director of the Company or a Related Company whom the Committee from time to time selects. An Award may also be granted to any consultant, agent, advisor or independent contractor for bona fide services rendered to the Company or any Related Company that (a) are not in connection with the offer and sale of the Company’s securities in a capital-raising transaction and (b) do not directly or indirectly promote or maintain a market for the Company’s securities.

 

21
 

 

Equity Compensation Plan Information

 

Plan Category   Number of Securities to be Issued Upon Excise of Outstanding Options, Warrants and Rights     Weighted-Average Exercise Price of Outstanding Options, Warrants and Rights     Number of Securities Remaining Available for Future Issuances Under Equity Compensation Plans*  
Equity compensation plans approved by security holders     12,223,321     $ 0.36       47,776,679  
Equity compensation plans not approved by security holders     -       -       -  
Total     12,223,321     $ 0.36       47,776,679  

 

  * Represents 2,000 Series C Preferred Shares on an as-converted basis and 8,812,801 shares of common stock available under the Plan.

 

Recent Sales of Unregistered Securities

 

On October 27, 2023, the Company completed the sale of a convertible promissory note in the principal amount of $156,250 to an accredited investor. The purchase price of the note was $156,250, representing a 20% original issue discount. The note is non-interest bearing, except in the case of the event of a default, in which case interest will accrue from the date of the default at a rate equal to the lower of 18% per annum or the maximum rate permitted by law. The note becomes due on October 27, 2024. The holder may elect to convert the principal amount of the note and default interest, if any, subject to adjustment at a price equal to 90% of the lowest daily volume weighted average price of the common stock during the fifteen trading days preceding the conversion date. The Company relied upon the exemption provided by Section 4(a)(2) of the Securities Act of 1933 in connection with this transaction.

 

During the three months ended December 31, 2023, the Company issued 3,300,000 shares of common stock upon the conversion of outstanding notes The Company relied upon the exemption provided by Section 3(a)(9) of the Securities Act of 1933 in connection with these issuances.

 

During the three months ended December 31, 2023, the Company issued 1,233,025 shares of common stock as payment for consulting and advisory service. The Company relied upon the exemption provided by Section 4(a)(2) of the Securities Act of 1933 in connection with these transactions.

 

In December 2023, the Company issues 1,364,154 shares of common stock in settlement of obligations under a purchase agreement. The Company relied upon the exemption provided by Section 4(a)(2) of the Securities Act of 1933 in connection with this transaction.

 

In December 2023, the Company 962,087 shares of common stock in settlement of $134,683 of indebtedness. The Company relied upon the exemption provided by Section 4(a)(2) of the Securities Act of 1933 in connection with this transaction.

 

In December 2023, the Company issued 464,409 shares of common stock in satisfaction of payments due under a note. The Company relied upon the exemption provided by Section 4(a)(2) of the Securities Act of 1933 in connection with this transaction.

 

In September 2023 the Company issued a convertible note in the principal amount of $10,000 for a purchase price of $15,000. The note has term of six months, bears interest at a rate of twelve percent per annum and is convertible into common stock at a price of $.0772 per share. In connection with this transaction, the Company issued the purchaser 100,000 shares of common stock. The Company relied upon the exemption provided by Section 4(a)(2) of the Securities Act of 1933 in connection with this transaction.

 

In December 2023 the Company issued a convertible note in the principal amount of $37,500 for a purchase price of $25,000. The note has term of six months, bears interest at a rate of twelve percent per annum and is convertible into common stock at a price of $.0772 per share. In connection with this transaction, the Company issued the purchaser 500,000 shares of common stock. The Company relied upon the exemption provided by Section 4(a)(2) of the Securities Act of 1933 in connection with this transaction.

 

In December 2023, the Company issued 9,167 shares of common stock in connection with the settlement of a litigation matter. The Company relied upon the exemption provided by Section 4(a)(2) of the Securities Act of 1933 in connection with this transaction.

 

22
 

 

Item 6. Selected Financial Data

 

Not required for smaller reporting companies.

 

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operation

 

General

 

Can B̅ Corp. was originally formed as a Florida corporation on October 11, 2005, under the name of WrapMail, Inc. Effective January 5, 2015, we acquired 100% ownership of Prosperity Systems, Inc., which the Company is in the process of dissolving. Effective December 28, 2018, we acquired 100% ownership of Pure Health Products. In November 2018, we formed Duramed as a wholly owned subsidiary. The Company is presently in the process of dissolving Prosperity.

 

The Company is in the business of promoting health and wellness through its development, manufacture and sale of products containing cannabinoids derived from hemp biomass and the licensing of durable medical devises. Can B̅’s products include oils, creams, moisturizers, isolate, gel caps, spa products, and concentrates and lifestyle products. Can B̅ develops its own line of proprietary products as well seeks synergistic value through acquisitions in the hemp industry. Can B̅ aims to be the premier provider of the highest quality hemp derived products on the market through sourcing the best raw material and offering a variety of products we believe will improve people’s lives in a variety of areas.

 

On March 14, 2024, an auction of the assets of our hemp division was conducted under Article 9 of the Uniform Commercial Code following allegations by Arena that we were in breach of our obligations under certain notes and a forbearance agreement. See “Item 3. Legal Proceedings.”

 

Following the auction, we have continued our hemp operations on a reduced scale using equipment provided by third parties and the services of third-party processors. Historically, revenues from our hemp division supported, in part, our durable medical equipment business conducted through Duramed. Due to reduced support from the hemp division, Duramed is operating with reduced staff which has adversely impacted revenues. While we plan to continue our hemp and durable medical equipment operations for the near term, our primary focus will be on protecting and commercializing the cannabis patents recently acquired by Nascent.

 

Results of Operations

 

    Year Ended December 31,  
    2023     2022     $ Change     % Change  
Revenues                        
Product sales   $ 1,336,117     $ 5,524,036     $ (4,187,919 )     -75.8 %
Service revenue     819,627       1,161,483       (341,856 )     -29.4 %
Total revenues     2,155,744       6,685,519       (4,529,775 )     -67.8 %
Cost of revenues     1,797,047       4,071,144       (2,274,097 )     -55.9 %
Gross profit     358,698       2,614,375       (2,255,677 )     -86.3 %
                                 
Operating expenses     7,845,140       16,782,522       (8,937,382 )     53.3 %
                                 
Loss from operations     (7,486,442 )     (14,168,147 )     6,681,705       -47.2 %
                                 
Other (expense) income:                                
Change in fair value of warrant liability     201,277       154,010       (16,762 )     -7.7 %
Interest expense     (2,510,811 )     (902,130 )     (1,851,417 )     280.8 %
Other expense     68,108       (7,115 )     72,928       -1513 %
Other expense     (2,241,426 )     (755,235 )     1,795,251       402.4 %
                                 
Loss before provision for income taxes     (9,727,868 )     (14,923,382 )     4,886,454       -33.4 %
                                 
Provision for income taxes     9,596       793       9,596       NA  
                                 
Net loss   $ (9,737,464 )   $ (14,924,175 )   $ 4,876,858       -33.4 %

 

Year Ended December 31, 2023 compared with Year Ended December 31, 2022:

 

Revenues decreased $4,529,775. The decrease largely due to the normalization of sales activity with 2022 positively impacted by the wind down of restrictions related to the Covid-19 Pandemic surrounding elective surgeries, enabling an increase in the usage of the Company’s Duramed product lines and ultrasound device associated with patient recovery.

 

Compensation expenses decreased $4,275,357 primarily related to a decrease in non-cash stock-based compensation expense.

 

Consulting and professional fees decreased $3,591,054 in 2023. The decrease relates to one time amount including legal, accounting, and other consulting fees and services incurred during the year ending December 31, 2022 related to an increase in legal fees and increase in consulting fees related to expansion of our durable medical device offerings as well as additional consulting fees related to formulation and development consulting related to hemp product development and other product enhancements which did not recur in 2023

 

Other operating expenses decreased $1,070,971 which is mainly due to decrease in rent expense from closing certain facilities and other cost saving initiatives.

 

23
 

 

Liquidity and Capital Resources

 

As of December 31, 2023, the Company had cash and cash equivalents of $34,006 and negative working capital of $5,747,103. Cash and cash equivalents decreased $31,519 compared to December 31, 2022. For the year ended December 31, 2023, $1,349,938 was provided by financing activities, and $1,311,838 was used in operating activities.

 

The Company currently has no agreements, arrangements, or understandings with any person to obtain funds through bank loans, lines of credit or any other sources.

 

We currently have no commitments with any person for any capital expenditures.

 

We have no off-balance sheet arrangements.

 

As of December 31, 2023 the Company had $8.9 million aggregate principal amount of notes that are past due. The Company plans to seek additional extensions of these notes or refinance the indebtedness. No assurance can be given that the Company will be successful in obtaining extensions or refinancing the indebtedness.

 

Item 7A. Quantitative and Qualitative Disclosure About Market Risk

 

Not applicable.

 

Item 8. Financial Statements and Supplementary Data

 

Our Consolidated Financial Statements and Notes thereto, for the fiscal years ended December 31, 2022 and 2021 and the report of BF Borgers CPA PC, our independent registered public accounting firm, are set forth on pages F-1 through F-25 of this Annual Report.

 

Item 9 Changes in and Disagreements With Accountants on Accounting and Financial Disclosure

 

N/A

 

Item 9A. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

Disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported, within the time period specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in the reports filed under the Exchange Act is accumulated and communicated to management, including the Chief Executive Officer (CEO), as appropriate, to allow timely decisions regarding required disclosure. Based on the evaluation, the CEO has concluded that our disclosure controls and procedures are ineffective to ensure that information disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms. This determination was based on the small size of our accounting staff and the lack of segregation of duties.

 

To address the material weaknesses, we performed additional analysis and other post-closing procedures in an effort to ensure our financial statements included in this annual report have been prepared in accordance with generally accepted accounting principles. Accordingly, management believes that the financial statements included in this report fairly present in all material respects our financial condition, results of operations and cash flows for the periods presented.

 

Management Report on Internal Control over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Our internal control system was designed to provide reasonable assurance to our management and board of directors regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.

 

24
 

 

Any internal control system, no matter how well designed, has inherent limitations and may not prevent or detect misstatements. Accordingly, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.

 

Management, with the participation of our Chief Executive Officer, has evaluated the effectiveness of our internal control over financial reporting as of December 31, 2023 based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this evaluation, because of the Company’s limited resources and limited number of employees, and the absence of an audit committee, management concluded that, as of December 31, 2023, our internal control over financial reporting is not effective in providing reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principle, which creates a material weakness. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis. A material weakness means there is a risk that our financial reports or other filings may contain an error or inaccuracy or not submitted timely.

 

There was a material weakness in the Company’s internal control over financial reporting due to the fact that the Company did not have an adequate process established to ensure appropriate levels of review of accounting and financial reporting matters, which resulted in our closing process not identifying all required adjustments and disclosures in a timely fashion. We expect that the Company will need to hire accounting personnel with the requisite knowledge to improve the levels of review of accounting and financial reporting matters. The Company may experience delays in doing so and any such additional employees would require time and training to learn the Company’s business and operating processes and procedures. For the near-term future, until such personnel are in place, this will continue to constitute a material weakness in the Company’s internal control over financial reporting that could result in material misstatements in the Company’s financial statements not being prevented or detected.

 

Changes in Internal Control over Financial Reporting

 

There have been no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Securities and Exchange Act of 1934) during the year ended December 31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

Item 9B. Other Information

 

None.

 

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

 

Not Applicable.

 

Item 10. Directors, Executive Officers and Corporate Governance

 

Our board of directors is to be elected annually by our shareholders. The board of directors elects our executive officers annually. Our directors and executive officers as of March 31, 2024 are as follows:

 

Name   Age   Position
Marco Alfonsi   63   CEO, Director and Chairman since June 15, 2017
Stanley L. Teeple   75   CFO, Secretary and Director since October 1, 2018
Frederick Alger Boyer, Jr.   55   Independent Director appointed October 9, 2019
James F. Murphy   76   Independent Director appointed October 9, 2019

 

Marco Alfonsi, CEO and Chairman Director has been a financial service professional for the past 20 years. Mr. Alfonsi was appointed director and CEO of the Company in or around January 2015. Immediately prior to that, he spent eight years serving as the CEO of Prosperity Systems, Inc.

 

25
 

 

Throughout his career, Mr. Alfonsi was directly and indirectly involved in raising over $100 million dollars for small and medium sized business. Prior to his involvement in the financial services industry, Mr. Alfonsi has owned, operated, financed and sold several businesses. Mr. Alfonsi successfully started and managed two companies (ExecuteDirect.com, and Bakers Express of New York, Inc.), and held senior management positions with a number of financial institutions, including: Global American Investments, Clark Street Capital and Basic Investors.

 

Stanley L. Teeple –Mr. Teeple, CFO, Secretary, Director, was engaged from 2017-2018 with Solis Tek, Inc. (OTCQB:SLTK) a California based publicly traded corporation as Senior Vice President, Corporate Secretary , and Chief Compliance Officer. Solis Tek, Inc. a NV Corporation, is a developer of lighting and nutrient products, and most recently in cultivation and processing for the cannabis industry. Previously, from 2015-2016 Mr. Teeple was Chief Financial Officer and Secretary for Zonzia Media, Inc. (OTC:ZONX), a provider of streaming video and content to cable subscribers and hotel networks throughout the eastern US. From 2008 to 2014 Mr. Teeple was Chief Financial Officer and Secretary of Indigo-Energy, Inc. (OTC:IDGG) a publicly traded company in the oil and gas exploration business. Over the prior three plus decades Mr. Teeple through his turnaround consulting business, Stan Teeple, Inc., has held numerous senior management positions in several public and private companies across a broad spectrum of industries. Additionally, he has operated and worked for various court appointed trustees and principals as CEO, COO, and CFO in the entertainment, pharmaceuticals, food, travel, and tech industries. He operated his consulting business on a project-to-project basis and holds various other directorships. His businesses operational strengths include knowing how to manage and maximize the resources and preserve the integrity of a company from start-up through to maturity and corporate compliance in a regulatory environment.

 

Frederick Alger Boyer, Jr. Independent Director, is President & CEO of Advance Care Medical, Inc. - Mr. Boyer has over 25 years of Wall Street experience having worked on both the investment side as well as the banking side of the business Most recently he served as Head of Equities for the New York based investment bank H.C. Wainwright & Co. where he had overseen efforts in capital markets, sales, and trading. Prior to that he worked and or supervised teams at Rodman & Renshaw, Oppenheimer, Piper Jaffray, and Credit Suisse in New York, San Francisco, and Minneapolis. In his various roles he has advised hundreds of companies in their financing efforts both publicly and privately. Mr. Boyer has numerous securities licenses and is a graduate of the University of California at Berkeley.

 

James F. Murphy, Independent Director, brings more than 40 years of investigative and consulting experience as the Founder and President of Sutton Associates. From 1980 to 1984, Mr. Murphy was an Assistant Special Agent in Charge with the Federal Bureau of Investigation, responsible for a territory encompassing more than seven million people. His investigative specialties included organized crime, white-collar crime, labor racketeering and political corruption. From 1976 to 1980, Mr. Murphy was assigned to the Office of Planning and Evaluation at FBI headquarters, Washington, D.C. In this capacity, he evaluated and recommended changes in the FBI’s administrative and investigative programs. Since entering the private sector in 1984, Mr. Murphy has advanced the industry by developing systematic and professional protocols for performing due diligence, as well as other investigative services.

 

26
 

 

Board Committees

 

We have established an audit committee, compensation committee, or nominating committee. With one of the independent Directors sitting as chair of each committee. Mr. Ronald Siver served as Chairman of the Nominating Committee until his resignation from the Board in July 2023 and the position is currently vacant. Mr. James Murphy is Chairman of the Audit Committee, and Mr. Alger Boyer is Chairman of the Compensation Committee.

 

Family Relationships

 

There are no familial relationships between any of our officers and directors.

 

Director or Officer Involvement in Certain Legal Proceedings

 

Our current directors and executive officers have not been involved in any legal proceedings as described in Item 401(f) of Regulation S-K in the past ten years.

 

Director Independence

 

The Company is not currently listed on any national securities exchange that has a requirement that the board of directors be independent. However, in anticipation of a possible exchange up listing, and in an effort toward better Board oversight, the company has engaged three independent Directors making the independent outside directors a majority on the Board of Directors.

 

Code of Ethics

 

We have adopted a Code of Ethics that applies to all of our employees and officers, and the members of our Board of Directors. This Code of Ethics is posted on the Company’s website www.canbiola.com and applies to all executive officers including CEO, CFO and COO.

 

Section 16(a) Beneficial Ownership Reporting Compliance

 

Section 16(a) of the Exchange Act requires our directors and executive officers, and persons who own more than 10% of a registered class of our equity securities, to file reports of ownership and changes in ownership with the SEC. Officers, directors and greater than 10% shareholders are required by SEC regulation to furnish the Company with copies of all Section 16(a) forms they file. Based on our review of the reports filed by Reporting Persons, we believe that, during the year ended December 31, 2023, the following Reporting Persons did not meet all applicable Section 16(a) filing requirements: (i) Stanley Teeple and (ii) Marco Alfonsi. Otherwise, we believe that the Reporting Persons met such filing requirements.

 

27
 

 

Item 11. Executive Compensation

 

The table below summarizes all compensation awarded to, earned by, or paid to our executive officers and directors for all services rendered in all capacities to us during the fiscal years ended December 31, 2023 and 2022.

 

Name and principal position   Year     Salary     Bonus     Stock awards     Option awards (4)     Non-equity incentive plan comp.     Non-qualified deferred comp. earnings     All other comp.     Total  
Marco Alfonsi (1)     2023     $ 10,000     $ 0     $ 0     $ 108,333     $ 0     $ 0     $ 0     $ 118,333  
      2022     $ 25,962     $ 0     $ 500,100     $ 100,000     $ 0     $ 0     $ 0     $ 626,062  
Stanley L. Teeple (2)     2023     $ 10,000     $ 0     $ 0     $ 108,333     $ 0     $ 0     $ 0     $ 118,333  
      2022     $ 25,962     $ 0     $ 500,100     $ 100,000     $ 0     $ 0     $ 0     $ 626,062  

 

(1) On December 28, 2020, Marco Alfonsi signed a three year Employment Agreement. Under that agreement, he was i) entitled to receive a base salary of fifteen thousand dollars ($15,000.00) per month, ii) was eligible to receive cash and or stock bonuses, iii) was entitled to receive a stock bonus in accordance with the Company’s Incentive Stock Option Plan (“ISOP”) in an amount of one-hundred thousand dollars ($100,000) per year of the Agreement, iv) issued 200 shares of the Company’s Series C Preferred Stock, and v) granted usual and customary benefits including expense reimbursement, health and life insurance plan reimbursements and allowances. Actual salary compensation was $25,962 during 2022 and $10,000 for 2023. In February 2024 the Company and Mr. Alfonsi entered into a new three year employment agreement containing terms substantially similar to the prior agreement except that the base salary was increased to $20,000 per month and the agreement provides that Mr. Alfonsi will be entitled to quarterly distributions of two percent (2%) of the total revenues received by the Company from Nascent during and after the term of the agreement.

 

(2) On December 28, 2020, Stanley Teeple entered into a three-year employment agreement with the Company. Under that agreement, he was i) entitled to receive base salary of fifteen thousand dollars ($15,000.00) per month, ii) eligible to receive cash and or stock bonuses, iii) entitled to receive a stock bonus in accordance with the Company’s ISOP in an amount of one-hundred thousand dollars ($100,000) per year of the Agreement, iv) issued 200 shares of the Company’s Series C Preferred Stock, and v) granted usual and customary benefits including expense reimbursement, health and life insurance plan reimbursements and allowances. Actual salary compensation was $25,962 during 2022 and $10,000 for 2023. In February 2024 the Company and Mr. Teeple entered into a new three year employment agreement containing terms substantially similar to the prior agreement except that the base salary was increased to $18,500 per month and the agreement provides that Mr. Teeple Alfonsi will be entitled to quarterly distributions of two percent (2%) of the total revenues received by the Company from Nascent during and after the term of the agreement.

 

As of December 31, 2023, there were Incentive Stock Option Awards issued to Marco Alfonsi and Stanley Teeple in the amount of $100,000 each. The Options were issued on December 29, 2020 under the ISO Plan, at a strike price of $.361 per share for 277,008 shares for each of the 4 persons named.

 

(5) The amounts reported in this column represent the grant date fair value of option awards granted during the years ended December 31, 2023 and 2022 in accordance with FASB ASC 718. The assumptions used in the calculation of these awards are discussed in Note 11 to the Consolidated Financial Statements included in this Report.

 

28
 

 

The table below summarizes all compensation awarded to, earned by, or paid to our non-interested directors for all services rendered in all capacities to us during the previous two fiscal years, as of December 31, 2022.

 

Non-Interested Director Summary Compensation Table
Name and principal position   Year   Fees Earned or Paid in Cash    

Stock awards

(1)

    Option awards (2)     Non-equity incentive plan comp.     Non-qualified deferred comp. earnings     All other com.     Total  
Frederick A. Boyer   2023   $ 0     $ 0     $ 0     $ 0     $ 0     $ 0     $ 0  
Director   2022   $ 0     $ 100,020     $ 0     $ 0     $ 0     $ 0     $ 100,020  
Ronald Silver   2023   $ 0     $ 0     $ 0     $ 0     $ 0     $ 0     $ 0  
Director (3)   2022   $ 0     $ 100,020     $ 0     $ 0     $ 0     $ 0     $ 100,020  
James F. Murphy   2023   $ 0     $       $ 0     $ 0     $ 0     $ 0     $ 0  
Director   2022   $ 0     $ 100,020     $ 0     $ 0     $ 0     $ 0     $ 100,020  

 

  1) Each of the 3 non-interested independent directors was issued 20 Preferred C shares in 2022.
  2) As of December 31, 2023, Directors Boyer, Silver and Murphy each owned 10,000 options to exercise and purchase stock at $.30 at any time until 2023.
  3) Mr. Silver resigned his position as Director in July 2023.

 

No director has received cash compensation for their directorship. We do have a compensation committee and compensation for our directors and officers is determined by our board of directors.

 

We reimburse Non-Employee Directors for actual out-of-pocket costs incurred to attend board meetings. No additional compensation is paid for attendance in person or by telephone at board meetings.

 

The table below summarizes all outstanding equity awards for officers, as of December 31, 2022.

 

Outstanding Equity Awards at Fiscal Year-End
Name and principal position   Grant Date     Grant Type     Number of Securities Underlying Unexercised Options Exercisable     Number of Securities Underlying Unexercised Options Unexercisable     Option Exercise Price     Option Expiration Date  
Stanley Teeple – CFO     10/21/2018       Stock Options       667       0     $ 4.50       10/20/2023  
                                                 
Marco Alfonsi – CEO     8/28/2022       Stock Options       100,000       0     $ 3.00       8/27/2027  
                                                 
Stanley Teeple – CFO     8/28/2022       Stock Options       100,000       0     $ 3.00       8/27/2027  

 

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

 

The following table sets forth the ownership, as of April 12, 2023, of our common stock, Series C Preferred Stock and Series D Preferred Stock by (i) each person known by us to be the beneficial own of more than five (5%) percent of the applicable class; (ii) each of the Company’s executive officers and directors; and (iii) the Company’s directors and executive officers as a group. To the best of our knowledge, the persons named have sole voting and investment power with respect to such shares, except as otherwise noted. There are not any pending or anticipated arrangements that may cause a change in control. The information presented below regarding beneficial ownership of our voting securities has been presented in accordance with the rules of the Securities and Exchange Commission and is not necessarily indicative of ownership for any other purpose. Under these rules, a person is deemed to be a “beneficial owner” of a security if that person has or shares the power to vote or direct the voting of the security or the power to dispose or direct the disposition of the security. A person is deemed to own beneficially any security as to which such person has the right to acquire sole or shared voting or investment power within 60 days through the conversion or exercise of any convertible security, warrant, option or other right. More than one person may be deemed to be a beneficial owner of the same securities.

 

29
 

 

Shares Beneficially Owned(1)

As of April 12, 2023

Name and Address of Beneficial Owner(2):  

Common

Stock

    Percent of Class(3)    

Series C

Preferred

Stock

    Percent of Class(4)    

Series D Preferred

Stock

    Percent of Class(5)    

Percent of Total Voting

Power

 
Marco Alfonsi, CEO and Director     3,620,805 (6)     6.90 %     300       27.3 %     1,250       31.3 %     7.89 %
                                                         
Stanley L. Teeple, CFO and Director     3,620,632 (7)     6.88 %     300       27.3 %     1,250       31.3 %     7.87 %
                                                         
Frederick A. Boyer, Director     1,008,668 (8)     2.00 %                             1.84 %
                                                         
James F. Murphey, Director     1,208,668 (9)     2.39 %                       -       2.20 %
                                                         
All directors and executive officers as a group (4 persons)     9,470,773       16.59 %     600       10.4 %     2,500       62.5 %     18.35 %
                                                         
Arena Special Opportunities Fund, L.P     5,421,840 (11)     9.9 %                             9.19 %
                                                         
Walleye Opportunities Master Fund LTD     5,421,840 (12)     9.9 %                                     9.19 %
                                                         
ClearThink Capital Partners     5,421,840 (13)     9.9 %                             9.46 %

 

(1) Shares of common stock subject to stock options, warrants or convertible securities currently exercisable or convertible, or exercisable or convertible within 60 days of April 12, 2023 are deemed to be outstanding for computing the percentage ownership of the person holding such options, warrants or convertible securities and the percentage ownership of any group of which the holder is a member, but are not deemed outstanding for computing the percentage ownership of any other person.
(2) Except as otherwise indicated, the address of each beneficial owner is c/o Can B Corp., 960 South Broadway, Suite 120, Hempstead, New York 11801.
(3) Based on 49,344,230 shares of common stock issued and outstanding as of April 12, 2023.
(4) Based on 1,100 shares of Series C Preferred Stock issued and outstanding as of April 12, 2023. Shares of Series C Preferred Stock entitle their holders to vote on an as converted basis (1,667 shares of common stock per share of Series C Preferred Stock).
(5) Based on 4,000 shares of Series D Preferred Stock issued and outstanding as of April 12, 2023. Holders of Series D Preferred Stock are entitled to 667 votes per share.
(6) Includes 2,774,965 shares of common stock issuable upon the exercise of options and 500,100 shares of common stock issuable upon conversion of 300 shares of Series C Preferred Stock. Does not include 42,343 shares of common stock held by adult members of Mr. Alfonsi’s family.
(7) Includes 2,778,526 shares of common stock issuable upon the exercise of options and 500,100 shares of common stock issuable upon conversion of 300 shares of Series C Preferred Stock.
(8) Includes 1,000,667 shares of common stock issuable upon the exercise of options.
(9) Includes 1,200,667 shares of common stock issuable upon the exercise of options.
(10) Includes 2,778,526 shares of common stock issuable upon the exercise of options and 500,100 shares of common stock issuable upon conversion of 300 shares of Series C Preferred Stock.
(11) Includes shares beneficially owned by the shareholder’s affiliates, Arena Investors, LP and Arena Special Opportunities Partners I, LP, and 4,650,146 shares issuable upon conversion of convertible securities and exercise of warrants that contain a 9.99% beneficial ownership limitation. The address of this shareholder is 405 Lexington Avenue, 59th Floor, New York, New York 10174.
(12) Includes 4,826,358 shares of common stock issuable upon conversion of convertible notes and exercise of warrants that contain a 9.99% beneficial ownership limitation. The address of this shareholder is 2800 Niagara Lane North, Plymouth Minnesota 55447.
(13) Includes 3,488,815 shares of common stock issuable upon conversion of convertible notes that contain a 9.99% beneficial ownership limitation

 

30
 

 

Item 13. Certain Relationships and Related Party Transactions, and Director Independence

 

Can B̅ Corp.’s Corporate Governance Guidelines establish standards for evaluating Director independence and requires that a majority of Directors be independent. The Board determines the independence of each Director under Nasdaq governance standards. Those standards identify the types of relationships that, if material, could impair independence. The Board determined that, under the Nasdaq listing standards, the following non-employee Directors are independent: Frederick A. Boyer, and James F. Murphy. Our non-independent directors are Marco Alfonsi and Stanley L. Teeple.

 

Except as described herein (or within the section entitled Executive Compensation of this report), none of the following parties (each a “Related Party”) has, in our fiscal years ended 2022 and 2021, had any material interest, direct or indirect, in any transaction with us or in any presently proposed transaction that has or will materially affect us:

 

  any of our directors or officers;
  any person who beneficially owns, directly or indirectly, shares carrying more than 10% of the voting rights attached to our outstanding shares of common stock; or
  any member of the immediate family (including spouse, parents, children, siblings and in- laws) of any of the above persons.

 

LI Accounting Associates, LLC (“LIA”), an entity controlled by a relative of the Managing Member PHP, is a vendor of Can B̅ Corp. As of December 31, 2023, the Company had accounts payable due to LIA of $_____. For the twelve months ended December 31, 2023, the Company had expenses to LIA of $______.

 

At December 31, 2023, the Company has amounts due to a director of the Company of approximately $____ which are expected to be repaid in the next twelve months.

 

Item 14. Principal Accounting Fees and Services

 

The following table sets forth fees billed to us by BF Borgers CPA PC, our independent registered public accounting firm during the fiscal years ended December 31, 2023 and December 31, 2022 for: (i) services rendered for the audit of our annual financial statements and the review of our quarterly financial statements; (ii) services by our independent registered public accounting firms that are reasonably related to the performance of the audit or review of our financial statements and that are not reported as audit fees; (iii) services rendered in connection with tax compliance, tax advice and tax planning; and (iv) all other fees for services rendered.

 

    December 31, 2023     December 31, 2022  
             
Audit Fees   $ 197,300     $ 197,300  
Audited Related Fees   $ 0     $ 0  
Tax Fees   $ 0     $ 0  
All Other Fees   $ 0     $ 0  

 

31
 

 

PART IV

 

Item 15. Exhibits, Financial Statement Schedules.

 

Exhibits Schedule

 

The following exhibits are filed with this Annual Report:

 

Exhibit   Description
2.1   Share Purchase Agreement with Prosperity Systems, Inc., dated January 5, 2015(2)
2.2   Membership Purchase Agreement with Pure Health Products(6)
2.3   Green Grow Stock Purchase Agreement(4)
2.4   Green Grow Modification Agreement(1)
3.1   Articles of Incorporation, as amended(1)
3.2   Bylaws(2)
4.1   Articles of Amendment designating Series A Preferred Stock rights, as amended(9)
4.2   Articles of Amendment designating Series B Preferred Stock rights(1)
4.3   Articles of Amendment designating Series C Preferred Stock rights(7)
4.4   Articles of Amendment designating Series D Preferred Stock rights(10)
10.1   Employment Agreement with Marco Alfonsi dated December 29, 2020(10)
10.2   Employment Agreement with Stanley L. Teeple dated December 29, 2020(10)
10.3   Employment Agreement with Pasquale Ferro dated December 29, 2020(10)
10.4   Employment Agreement with Phil Scala dated December 29, 2020(10)
10.5   Commission Agreement with Andrew Holtmeyer(10)
10.6   Employment Agreement with Bradley Lebsock(10)
10.7   Memorandum of Understanding with Sam International and ZetrOZ Systems LLC(3)
10.8   Can B̅ Corp. 2020 Incentive Stock Option Plan(8)
10.9   Arena Securities Purchase Agreement(10)
10.10   ASOF Original Issue Discount Senior Secured Convertible Promissory Note(10)
10.11   ASOF Warrant to Purchase Common Stock(10)
10.12   ASOP Original Issue Discount Senior Secured Convertible Promissory Note(10)
10.14   ASOP Warrant to Purchase Common Stock(10)
10.15   Arena Security Agreement(10)
10.16   Arena Intellectual Property Security Agreement(10)
10.17   Arena Registration Rights Agreement(10)
10.18   Arena Holding Escrow Agreement(10)
10.19   Arena Guaranty Agreement from Company Subsidiaries(10)
10.20   Amendment to 2020 ASOF Promissory Note(11)
10.21   Amendment to 2020 ASOP Promissory Note(11)
10.22   2021 Arena Securities Purchase Agreement(11)
10.23   2021 ASOF Original Issue Discount Senior Secured Convertible Promissory Note(11)
10.24   2021 ASOF Warrant to Purchase Common Stock(11)
10.25   2021 ASOP Original Issue Discount Senior Secured Convertible Promissory Note(11)
10.26   2021 ASOP Warrant to Purchase Common Stock(11)
10.27   2021 Arena Registration Rights Agreement(11)
10.28   2021 Addendum to Arena Security Agreement(11)

 

32
 

 

10.29   2021 Addendum to Arena Intellectual Property Security Agreement(11)
10.30   2021 Addendum to Arena Guaranty Agreement from Company Subsidiaries(11)
10.31   Asset Acquisition Agreement with Imbibe(10)
10.32   Equipment Acquisition Agreement with TWS(12)
10.33   Promissory Note to TWS(12)
10.34   Asset Purchase Agreement with MCB(12)
10.35   Commercial Lease with Makers Developments LLC(13)
10.36   Single-Tenant NNN Lease Agreement with CS2 Real Estate Holdings, LLC(13)
10.37   Commercial Lease with Red Road Business Park(13)
10.38   Asset Acquisition Agreement with various Sellers (Botanical Biotech)(10)
10.39   PrimeX Distribution Agreement(15)
10.40   American Development Partners development agreement(15)
10.41   Mast Hill Securities Purchase and Related Agreements(14)
10.42   Blue Lake Partners Securities Purchase and Related Agreements(14)
10.43   Fourth Man Securities Purchase and Related Agreements(16)
10.44   Extension and Amendment to Arena Transactional Documents(16)
10.45   Amended Placement Agent Agreement(18)
10.46   Alumni Capital Securities Purchase and Related Documents(19)
10.47   Arena Exchange Agreement(20)
10.48   Agreement with Forever Bradst(21)
10.49   Promissory Note Modification Agreement with TWS Pharma LLC(22)
10.50   Walleye Securities Purchase Agreement(22)
10.51   Walleye Promissory Note(22)
10.52   Walleye Revenue Pledge and Security Agreement(22)
10.53   Walleye Common Stock Purchase Warrant(22)
10.54   Amendment to Walleye Common Stock Purchase Agreement(22)
10.55   Walleye Registration Rights Agreement(22)
10.56   Intercreditor Agreement among Can B Corp., Walleye and Arena(22)
10.57   Arena Forbearance Agreement(22)
10.58   Amendment No. 2 to Blue Lake Partners Promissory Note and Amendment to Securities Purchase Agreement, Consent and Waiver Agreement(22)
10.59   Amendment No. 2 to Mast Hill Fund Promissory Note, Amendment to Securities Purchase Agreement, Consent and Waiver Agreement(22)
10.60   Amendment No. 2 to Fourth Man Promissory Note, Amendment to Securities Purchase Agreement, Consent and Waiver Agreement(22)
10.61   Walleye May 2023 Promissory Note(23)
10.62   Securities Purchase Agreement dated as of October 26, 2023 between Can B Corp. and Walleye Opportunities Master Fund Ltd.(24)
10.63   Promissory Note dated October 27, 2023 issued by Can B Corp. to Walleye Opportunities Master Fund Ltd.(24)
10.64   Consolidated Note dated October 27, 2023 issued by Can B Corp. to Walleye Opportunities Master Fund Ltd.(24)
10.65   Distribution and Assignment Agreement dated as of October 27, 2023 among Can B Corp, Nascent Pharma, LLC and Walleye Opportunities Master Fund Ltd.(24)
10.66   Registration Rights Agreement dated as of October 27, 2023 between Can B Corp and Walleye Opportunities Master Fund Ltd.(24)
10.67   Employment Agreement with Marco Alfonsi dated February 8, 2024
10.68   Employment Agreement with Stanley Teeple dated  February 8, 2024
10.69   Amendment Modification to Convertible Promissory Note dated August 7, 2023 between Can B Corp. and ClearThink Capital Partners, LLC
10.70   Promissory Note dated September 22, 2023 issued by Can B Corp. to ClearThink Capital Partners, LLC
10.71   Promissory Note dated December 20, 2023 issued by Can B Corp. to ClearThink Capital Partners, LLC
10.72   Promissory Note dated February 29, 2024 issued by Can B Corp. to ClearThink Capital Partners, LLC
14.1   Code of Ethics(1)
21.1   List of Subsidiaries(10)
31.1   Chief Executive Officer certification under Section 302 of the Sarbanes-Oxley Act of 2002
31.2   Chief Financial Officer certification under Section 302 of the Sarbanes-Oxley Act of 2002
32.1   Chief Executive Officer certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

33
 

 

101.INS   Inline XBRL Instance Document
101.SCH   Inline XBRL Taxonomy Extension Schema
101.CAL   Inline XBRL Taxonomy Extension Calculation
101.DEF   Inline XBRL Taxonomy Extension Definition
101.LAB   Inline XBRL Taxonomy Extension Labels
101.PRE   Inline XBRL Taxonomy Extension Presentation
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

(1) Filed with the Annual Report on Form 10-K filed with the SEC on April 2, 2020 and incorporated herein by reference.
(2) Filed with the Form S-1 Registration Statement filed with the SEC on December 2, 2015 and incorporated herein by reference.
(3) Filed with the Current Report on Form 8-K filed with the SEC on January 30, 2019 and incorporated herein by reference.
(4) Filed with the Current Report on Form 8-K filed with the SEC on December 6, 2019 and incorporated herein by reference.
(5) Filed with the Current Report on Form 8-K filed with the SEC on February 18, 2020 and incorporated herein by reference.
(6) Filed with the Current Report on Form 8-K filed with the SEC on January 15, 2019 and incorporated herein by reference.
(7) Filed with the Form 1-A/A, Part II, filed with the SEC on July 17, 2020 and incorporated herein by reference.
(8) Filed with the Form 1-A POS, Part II, filed with the SEC on September 11, 2020 and incorporated herein by reference.
(9) Filed with the Current Report on Form 8-K filed with the SEC on November 23, 2020 and incorporated herein by reference.
(10) Filed with the Annual Report on Form 10-K filed with the SEC on April 15, 2022 and incorporated herein by reference.
(11) Filed with the Quarterly Report on Form 10-Q filed with the SEC on May 21, 2021 and incorporated herein by reference.
(12) Filed with the Current Report on Form 8-K filed with the SEC on August 17, 2021 and incorporated herein by reference.
(13) Filed with the Current Report on Form 8-K filed with the SEC on September 1, 2021 and incorporated herein by reference.
(14) Filed with the Current Report on Form 8-K filed with the SEC on March 31, 2022 and incorporated herein by reference.
(15) Filed with the Form 10-K filed with the SEC on April 15, 2022 and incorporated herein by reference.
(16) Filed with the Current Report on Form 8-K filed with the SEC on April 29, 2022 and incorporated herein by reference.
(17) Filed with Form S-1/A filed with the SEC on February 14, 2022 and incorporated herein by reference.
(18) Filed with Form S-1/A filed with the SEC on May 25, 2022 and incorporated herein by reference.
(19) Filed with the Current Report on Form 8-K filed with the SEC on June 15, 2022 and incorporated herein by reference.
(20) Filed with Form S-1/A filed with the SEC on May 25, 2022 and incorporated herein by reference.
(21) Filed with the Current Report on Form 8-K filed with the SEC on July 25, 2022 and incorporated herein by reference.
(22) Filed with the Annual Report on Form 10-K filed with the SEC on April 17, 2023 and incorporated herein by reference.
(23) Filed with the Quarterly Report on Form 10-Q filed with the SEC on May 22, 2023 and incorporated herein by reference.
(24) Filed with the Current Report on Form 8-K filed with the SEC on November 3, 2023 and incorporated herein by reference.

 

34
 

 

SIGNATURES

 

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Can B̅ Corp.
     
Date: April 15, 2024 By: /s/ Marco Alfonsi
  Name: Marco Alfonsi
  Title: Chief Executive Officer
    (Principal Executive Officer and Principal Accounting Officer)
     
Date: April 15, 2024 By: /s/ Stanley L. Teeple
  Name: Stanley L. Teeple
  Title: Chief Financial Officer

 

In accordance with the Exchange Act, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

Signature   Title   Date
         
/s/ Marco Alfonsi   Chief Executive Officer, Director and Chairman   April 15, 2024
Marco Alfonsi   (Principal Executive Officer)    
         
/s/ Stanley L. Teeple   Secretary, CFO and Director   April 15, 2024
Stanley L. Teeple   (Principal Financial and Accounting Officer)    
         
/s/ Frederick Alger Boyer Jr.   Independent Director   April 15, 2024
Frederick Alger Boyer Jr.        
         
/s/ James Murphy   Independent Director   April 15, 2024
James Murphy        

 

35
 

 

Can B Corp. and Subsidiaries  
Index to Financial Statements  
   
Consolidated Financial Statements  
   
Report of Independent Registered Public Accounting Firm F-2
   
Consolidated Balance Sheets F-3
   
Consolidated Statements of Operations F-4
   
Consolidated Statements of Stockholders’ Equity F-5
   
Consolidated Statements of Cash Flows F-6
   
Notes to Consolidated Financial Statements. F-7

 

F-1

 

 

Report of Independent Registered Public Accounting Firm

 

To the shareholders and the board of directors of Can B Corp.

 

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheets of Can B Corp. as of December 31, 2023 and 2022, the related statements of operations, stockholders’ equity (deficit), and cash flows for the years then ended, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States.

 

Substantial Doubt about the Company’s Ability to Continue as a Going Concern

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company’s significant operating losses raise substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Basis for Opinion

 

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

 

Critical Audit Matter

 

Critical audit matters are matters arising from the current-period audit of the financial statements that were communicated or required to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments.

 

We determined that there are no critical audit matters.

 

/S/ BF Borgers CPA PC (PCAOB ID 5041)

We have served as the Company’s auditor since 2021

Lakewood, CO

April 15, 2024

 

F-2

 

 

Can B̅ Corp. and Subsidiaries

Consolidated Balance Sheets

 

   December 31, 2023   December 31, 2022 
Assets          
Current assets:          
Cash and cash equivalents  $34,006   $73,194 
Accounts receivable, less allowance for doubtful accounts of $2,818,395 and $985,028 at December 31, 2023 and 2022, respectively   3,723,344    6,586,210 
Inventory   1,619,542    2,024,053 
Prepaid expenses and other current assets   4,138    21,024 
Total current assets   5,381,029    8,704,481 
           
Other assets:          
Deposits   235,418    165,787 
Intangible assets, net   95,144    107,144 
Property and equipment, net   4,106,283    5,432,357 
Right of use assets, net   295,151    1,136,883 
Other noncurrent assets   13,139    13,139 
Total other assets   4,745,135    6,855,310 
           
Total assets  $10,126,164   $15,559,791 
           
Liabilities and Stockholders’ Equity          
Current liabilities:          
Accounts payable  $1,945,243   $3,140,408 
Accrued expenses   -    181,700 
Due to related party   357,243    295,243 
Notes and loans payable, net   8,569,489    7,951,196 
Warrant liabilities   1,766    203,043 
Operating lease liability - current   254,391    652,172 
Total current liabilities   11,128,132    12,423,762 
           
Long-term liabilities:          
Operating lease liability - noncurrent   -    438,104 
Total long-term liabilities   -    438,104 
           
Total liabilities  $11,128,132   $12,861,866 
           
Commitments and contingencies (Note 14)   -    - 
           
Stockholders’ equity:          
Preferred stock, authorized 5,000,000 shares:          
Series A Preferred stock, no par value: 20 shares authorized, 5 shares and 20 shares issued and outstanding at December 31, 2023 and 2022, respectively   5,320,000    5,320,000 
Series B Preferred stock, $0.001 par value: 500,000 shares authorized, 0 issued and outstanding   -    - 
Series C Preferred stock, $0.001 par value: 2,000 shares authorized, 1,100 and 23 issued and outstanding at December 31, 2023 and 2022, respectfully   2,900,039    2,900,039 
Series D Preferred stock, $0.001 par value: 4,000 shares authorized, 4,000 and 1,950 issued and outstanding at December 31, 2023 and 2022, respectfully   4    4 
Common stock, no par value; 1,500,000,000 shares authorized, 4,422,584 and 2,834,755 issued and outstanding at December 31, 2023 and 2022, respectively   83,263,105    79,614,986 
Common stock issuable, no par value; 36,248 and 0 shares at December 31, 2023 and 2022, respectively   119,586    119,586 
Treasury stock   (572,678)   (572,678)
Additional paid-in capital   10,396,274    8,006,822 
Accumulated deficit   (102,428,298)   (92,690,834)
Total stockholders’ equity   (1,001,968)   2,697,925 
           
Total liabilities and stockholders’ equity  $10,126,164   $15,559,791 

 

See notes to consolidated financial statements

 

F-3

 

 

Can B̅ Corp. and Subsidiaries

Consolidated Statement of Operations

 

   2023   2022 
   Year Ended December 31, 
   2023   2022 
Revenues          
Product sales  $1,336,117   $5,524,036 
Service revenue   819,627    1,161,483 
Total revenues   2,155,744    6,685,519 
Cost of revenues   1,797,047    4,071,144 
Gross profit   358,698    2,614,375 
           
Operating Expenses          
Compensation   2,923,858    7,199,215 
Consulting and professional fees   1,824,952    5,416,006 
Other operating expenses   3,096,330    4,167,301 
Total operating expenses   7,845,140    16,782,522 
           
Loss from operations   (7,486,442)   (14,168,147)
           
Other (expense) income:          
Change in fair value of warrant liability   201,277    154,010 
Interest expense   (2,510,811)   (902,130)
Other income/(expense)   68,108    (7,115 
Other expense   (2,241,426)   (755,235)
           
Loss before provision for income taxes   (9,727,868)   (14,923,382)
           
Provision for income taxes   9,596    793 
           
Net loss  $(9,737,464)  $(14,924,175)
           
Loss per share - basic and diluted  $(0.77)  $(4.18)
Weighted average shares outstanding - basic and diluted   12,590,147    3,570,087 

 

See notes to consolidated financial statements

 

F-4

 

 

Can B̅ Corp. and Subsidiaries

Consolidated Statements of Stockholders’ Equity

 

Years ended December 31, 2023 and 2022

 

   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Issuable   Shares   Amount   Capital   Deficit   Total 
  

Series A

Preferred Stock

  

Series B

Preferred Stock

   Series C
Preferred Stock
   Series D Preferred Stock   Common Stock   Common Stock   Treasury Stock   Additional Paid-in   Accumulated     
   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Issuable   Shares   Amount   Capital   Deficit   Total 
Balance, December 31, 2021   20   $28,440,000    0   $-    23   $207,000    1,950   $2    2,834,755   $49,676,847   $-    36,248   $(572,678)  $5,635,003   $(77,766,659)  $5,619,515 
                                                                                 
Conversion of Series A Preferred stock to Common stock   (15)   (23,120,000)   -    -    -    -    -    -    33,345    23,120,000    -    -    -    -    -    - 
                                                                                 
Issuance of preferred stock   -    -    -    -    -    -    2,050    2    -    -    -    -    -    -    -    2 
                                                                                 
Sale of common stock   -    -    -    -    -    -    -    -    51,282    500,000    -    -    -    -    -    500,000 
                                                                                 
Issuance of common stock in lieu of note interest repayments   -    -    -    -    -    -    -    -    10,150    73,078    -    -    -    -    -    73,078 
                                                                                 
Issuance of common stock for services rendered   -    -    -    -    -    -    -    -    1,270,616    4,370,256    119,586    -    -    -    -    4,489,842 
                                                                                 
Issuance of common stock for equipment   -    -    -    -    -    -    -    -    13,704    98,666    -    -    -    -    -    98,666 
                                                                                 
Issuance of common stock for asset acquisition   -    -    -    -    -    -    -    -    190,505    1,767,498    -    -    -    -    -    1,767,498 
                                                                                 
Issuance of common stock resulting from the exercise of warrants   -    -    -    -    -    -    -    -    18,227    8,641    -    -    -    -    -    8,641 
                                                                                 
Stock-based compensation   -    -    -    -    1,077    2,693,039    -    -    -    -    -    -    -    2,371,819    -    5,064,858 
                                                                                 
Net loss   -    -    -    -    -    -    -    -    -    -    -    -    -    -    (14,924,175)   (14,924,175)
                                                                                 
Balance, December 31, 2022   5   $5,320,000    0   $-    1,100   $2,900,039    4,000   $4    4,422,584   $79,614,986   $119,586    36,248   $(572,678)  $8,006,822   $(92,690,834)  $2,697,925 
                                                                                 
Issuance of common stock for services rendered   -    -    -    -    -    -    -    -    3,965,385    1,046,194    -    -    -    -    -    1,046,194 
                                                                                 
Issuance of common stock for purchase of equipment   -    -    -    -    -    -    -    -    125,000    46,875    -    -    -    -    -    46,875 
                                                                                 
Warrants issued in connection with the issuance of convertible note   -    -    -    -    -    -    -    -    -    -    -    -    -    937,787    -    937,787 
                                                                                 
Issuance of common stock for for wages and salaries   -    -    -    -    -    -    -    -    6,940,118    589,216    -    -    -    -    -    589,216 
                                                                                 
Issuance of common stock for purchase of inventory   -    -    -    -    -    -    -    -    675,000    175,500    -    -    -    -    -    175,500 
                                                                                 
Issuance of common stock in lieu of interest payments   -    -    -    -    -    -    -    -    3,224,474    328,932    -    -    -    -    -    328,932 
                                                                                 
Issuance of common stock or legal settlement   -    -    -    -    -    -    -    -    1,419,156    185,499    -    -    -    -    -    185,499 
                                                                                 
Issuance of common stock in lieu of note repayments   -    -    -    -    -    -    -    -    11,981,479    1,275,903    -    -    -    -    -    1,275,903 
                                                                                 
Stock-based compensation   -    -    -    -    -    -    -    -    -    -    -    -    -    1,451665    -    1,451,665 
                                                                                 
Net loss   -    -    -    -    -    -    -    -    -    -    -    -    -    -    (9,737,464)   (9,737,464)
                                                                                 
Balance, December 31, 2023   5   $5,320,000    -   $-    1,100   $2,900,039    4,000   $4    32,753,196   $83,263,105   $119,586    36,248   $(572,678)  $10,396,274   $(102,428,298)  $(1,001,968)

 

See notes to consolidated financial statements

 

F-5

 

 

Can B̅ Corp. and Subsidiaries

Consolidated Statements of Cash Flows

 

   2022   2022 
   Year Ended December 31, 
   2022   2022 
Operating activities:          
Net loss  $(9,737,464)  $(14,924,175)
Adjustments to reconcile net loss to net cash used in operating activities:          
Stock-based compensation   1,451,665    5,064,860 
Common stock in lieu of cash payroll   589,216    - 
Depreciation   1,387,949    1,408,061